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The purinergic receptor P2X4 is a ligand-gated, non-selective cation channel, activated by 
ATP. This receptor is involved in pathophysiological processes including inflammatory pain 
and cardiac function. Selective inhibition of P2X4 is seen as a possible therapy, however 
little is known about the limited number of selective antagonists available. This study 
characterises the activity of 5-BDBD (one such antagonist). There is conflicting evidence for 
the action of this molecule with one prominent paper suggesting that 5-BDBD is a 
competitive antagonist and another suggesting that it interacts allosterically. The aims of 
this study were, to determine the mode of action for 5-BDBD and to identify residues 
responsible for mediating the effects of 5-BDBD. 
When challenging an ATP concentration response curve with various concentrations of 5-
BDBD, a reduction in the maximal response (at 20 and 30µM of 5-BDBD) and a decrease in 
potency (at 10, 20 and 30µM of 5-BDBD) were found. This suggested that 5-BDBD acts 
allosterically. A scan of the receptor was conducted using 10 amino acid chimeras (P2X4 
substituted for aligned insensitive P2X2). This scan used 30µM of ATP and 20µM of 5-BDBD 
to test for inhibition of the chimeric receptors. There was one chimera (at residues 81-90) 
which produced a significantly lower inhibition of response than the wildtype (p=4.8x10-4). 
An inhibition of 29.43% was found, compared to the wildtype inhibition of 72.1% with a 
range for the remaining chimeras of 70.5% to 85.6%.  Within this region residue 81 was 
unique to P2X4 (a phenylalanine residue which was replaced by a histidine residue from 
P2X2) and when tested, gave a significantly lower inhibition of 42.73% compared to the wild 
type at 79.2% (P=0.009). This implicates residue 81 with eliciting the inhibitory effect of 5-
BDBD on P2X4. 
The hope is that these findings can help to determine the binding pocket of 5-BDBD at P2X4, 












Table of Contents 
Abstract……………………………………………………………………………………………………………………………2 
Table of Contents………………………………………………………………………………….………………….………3 
List of figures and tables.………………………………………………………………………………….………………5 
List of abbreviations…………………………………………………………………………………………………………6  
Acknowledgements………………………………………………………………………………………………………….8  
Chapter1: Introduction………………………………………………………………………………….…………….……9 
1.1. Purinergic Receptors…………………………………………....………………………………………..….9 
1.2. P2X Receptors………………………………………………………………………………………………….10 
1.3. P2X4 Receptors………………………………………………………………………………………………..12 
1.4. Receptor Pharmacology……………………………………………………………………………………14 
1.5. 5-BDBD…………………………………………………………………………………………………………….16 
1.6. Aims and Hypotheses……………………………………………………………………………………….19 
Chapter 2: Materials & Methods…………………………………………………………………………………….20 




2.1.4 SBS and LB preparation………………………………………………………………………21 
2.1.5 Plate preparation………………………………………………………………………………..22 
2.2. Transfection……………………………………………………………………………………………………..22 
2.3. DNA Extraction…………………………………………………………………………………………………23 
2.4. Mutagenesis…………………………………………………………………………………………………….23 
2.4.1 Designing primers……………………………………………………………………………….23 
2.4.2 PCR……………………………………………………………………………………………………..24 
2.4.3 KLD reaction……………………………………………………………………………………….24 
2.4.4 transformation……………………………………………………………………………………24 
 2.4.5 DNA Extraction and Testing……………………………………………………………….25 
2.5. Flexstation Protocols………………………………………………………………………………………..25 
4 
 
2.6. Data Analysis…………………………………………………………………………………………………...25 
Chapter 3: Results………………………………………………………………………………………………………….27 
3.1. Transfection Protocol………………………………………………………………………………………27 
3.2. ATP Concentration Response……………………………………………..……………………………29 
3.3. IC50 Curve Derivation………………………………………………………………………………………31 
3.4. The Effect of 5-BDBD on a hP2X4 Trace……………………………………………………………33 
3.5. 5-BDBD Concentration Response…………………………………………………..…………………34 
3.6. Functional P2X2 Mutant Scan of the Receptor…………………………………………………37 
3.7. Point mutation within the 81-90 chimera………………………………………………………...38 
3.8. ATP Concentration response curves for the mutants of interest………………………39 
Chapter 4: Discussion……………………………………………………………………………………………………..40 
4.1. Transfection Optimisation………………………………………………………………………………..40 
4.2. hP2X4 and hP2X2 EC50 and IC50 Value Derivation………………………….……………….42 
4.3. 5-BDBD Concentration  Response Curves…………………………………………………………43 
4.4. Functional Mutant Receptor Scan…………………………………………………………………….45 
4.5. Residues 81 to 90……………………………………………………………………………………………..46 
4.5.1 Residue 81………………………………………………………………………………………….47 
4.5.2 Residue 83………………………………………………………………………………………….48 
4.5.3 Residue 87and 88……………………………………………………………………………….48 
4.5.4 Residue 81 Percentage Inhibition Derivation ….………………………………….49 











List of Figures and Tables 
Figures 
Figure 1.1- Stimulation of purinergic receptors……………………………………………………..……………10 
Figure 1.2- P2X monomer and trimer quaternary structure…………………………………………..……11 
Figure 1.3- Open and closed state zfP2X4 channel………..………………………………………………..….15 
Figure 1.4- 5-BDBD structure …………………………………………….…………………………………………..….17 
Figure 3.1- Polyfect and FuGene transfection reagent scan………………………………………………..27 
Figure 3.2- X-treme gene transfection reagent scan……………………………………………………………28 
Figure 3.3- Lipofectamine transfection reagent scan………………………………………………………….28 
Figure 3.4- hP2X4 ATP Concentration response curve………………………………………………………..29 
Figure 3.5- hP2X2 ATP Concentration response curve……………………………………….……………….30 
Figure 3.6- hP2X4 IC50 curve………………………………………………………………………………………………31 
Figure 3.7- hP2X2 IC50 curve………………………………………………………………………………………………32 
Figure 3.8- 20µM 5-BDBD trace for hP2X4………………………………………………………………………….33 
Figure 3.9- ATP Concentration response in the presence for 5-BDBD (1µM- 30µM).………….34 
Figure 3.10- 5-BDBD ATP Concentration response curves on one graph……….……………………36 
Figure 3.11- P2X4 functional mutant scan, with P2X4 monomer for context........................37 
Figure 3.12- A comparison WT to 81 point mutant response reduction……………………………..38 
Figure 3.13- ATP Concentration response curves for the mutant receptors of interest.……..39 
Figure 4.1- The chemical structures of 5-BDBD and Phenylalanine……………………………………..47 
Figure 4.2- The P2X4 ATP binding site relative to residue 81………………………………………………50 
 
Tables  
Table 1- PCR methods…………………………………………………………………………………………………………24 
Table 2- 5-BDBD concentration dependent response…………………..…………………………………….35 






List of Abbreviations 
AD- Alzheimer’s Disease 
ADP- Adenosine Diphosphate 
ANOVA- Analysis of Variance 
ATP- Adenosine Triphosphate 
BDNF- Bone-Derived Neurotrophic Factor 
BX430- N-[2,6-Dibromo-4-(1-methylethyl)phenyl]-N'-(3-pyridinyl)urea 
Ca2+- Calcium Ion 
CaSR- Calcium Sensing Receptor 
DAG- Diacylglycerol 
DMEM- Dulbecco’s Modified Eagle’s Media 
DMSO- Dimethyl Sulphoxide 
DNA- Deoxyribose Nucleic Acid 
EC50- Half maximal agonist concentration 
ECaC- Epithelial Calcium Channels 
E. coli – Escherichia coli 
eNOS- Endothelial Nitric Oxide Synthase 
ER- Endoplasmic Reticulum 
FBS- Foetal Bovine Serum 
F Ratio- Fluorescence Ratio 
GPCR-G-Protein Coupled Receptors  
HEK 293- Human Embryonic Kidney 293 cells 
HeLa- Henrietta Lacks cells 
hP2X4- Human P2X4 receptor 
IC50- Half maximal antagonist concentration 
KLD- Kinase, Lipase and Dpnl  
LB- Loading Buffer 
Na+- Sodium Ion 
NO- Nitrous Oxide 
7 
 
PBS- Phosphate Buffered Saline  
PCR- Polymerase Chain Reaction 
PGE2- Prostaglandin E2 
PLC- Phopholipase C 
PPADS- pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid 
PSB-12062- N-(p-methylphenylsulfonyl)phenoxazine 
PTH- Parathyroid Hormone 
RA- Rheumatoid Arthritis 
RNA- Ribonucleic Acid 
RPM- Rotations Per Minute 
RTK- Receptor Tyrosine Kinase 
SBS- Salt Buffered Saline 
SEM- Standard Error of Mean 
SR- Sarcoplasmic Reticulum 
STC-1- Stanniocalcin-1 
TM- Transmembrane 
UTP – Uridine Triphosphate 
WT- Wildtype 














I am very grateful for the opportunity that has been afforded to me by Dr Sam Fountain as I 
believe that the environment which he and the other members of his lab has created, has 
aided me in every aspect of my masters. As my supervisor Dr Fountain has been generous 
with his time and given any help I have needed throughout this year, providing ideas which 
have helped to further my project and make it succeed to the extent that it has. 
I would also like to thank all of all of the other members of Dr Fountain’s labs as they have 
all helped me to settle in and with any queries I have had along the way. In particular I 
would like to credit Dr David Richards and Sean Cullum due to them teaching me all of the 
lab techniques which I would go on to use throughout this project and producing the 
mutant library which would be very important for my scan of the receptor. Other notable 
contributions were made by Anna Fortuny-Gomez, Jessica Meades, Dr Mary Gonzalez 
Montelongo, Mohamed Elday and Dr Neville Ngum. 
Finally, I would like to thank my friends and family for the support that they have given me 





















Chapter 1: Introduction 
1.1 Purinergic Signalling 
Purinergic receptors are a family of receptors which can be stimulated by extracellular 
adenosine triphosphate (ATP) (P2X and P2Y), adenosine diphosphate (ADP) (P2Y) or 
Adenosine (P1 purinoreceptors). P1 receptors are denoted with the A (P1A1, P1A2a) and the 
P2 subtype are denoted with a P (P2Y1, P2X3) (Waxham, 2013).  P2 receptors are further 
divided into 2 different phenotypes (P2X and P2Y) (Burnstock, 2014). The P originally stood 
for purinergic, but it was later found that P2 receptors bound to pyrimidines preferentially 
over ATP, so now the P is designated to either purine or pyrimidine. P1 receptors can also be 
stimulated by synthetic adenosine and P2 receptors by synthetic analogues of ATP and UTP.  
When Geoffrey Burnstock first proposed the idea of purinergic receptors it was met with 
some scepticism. This was in some way due to ATP already having an important role as an 
intracellular energy source and therefore it was believed to be unlikely to act as a 
neurotransmitter as well (Burnstock, 2006). Over the 1970’s and 80’s evidence for the 
‘purinergic theory’ mounted and the idea became widely accepted by 1998 when four P1 
receptors were cloned and characterised (Ravelic et al, 1998). Purinergic receptors are now 
known to be widespread in mammalian cells and involved in numerous processes including 
pain responses, hormone secretion, cardiovascular regulation, cell proliferation, 
inflammation and apoptosis.  
Purinergic receptors can be involved in both short-term and long-term signalling. For an 
example of short-term signalling, P2Y receptors are involved in the regulation of ion 
transport for epithelial cells which can have implications for diseases such as Cystic Fibrosis 
where activation of these receptors can lead to reduced mucous clearance and chronic 
infection. This occurs due to the increased chloride secretion resulting in thicker mucous. 
For an example of long-term signalling, several P2Y receptors and P2X5 play a key role in 
DNA synthesis and cell proliferation which was proven to be the case in mice (Neary et al, 
1996) and rat thyroid cells (Ekokoski et al, 2001). More recently the focus has been moved 
towards purinergic receptors being therapeutic targets for many diseases including epilepsy, 
atherosclerosis, Alzheimer’s, depression and cancer (Burnstock, 2017: Sarti et al, 2018). 
P1 receptors are G protein coupled receptors which are endogenously activated by 
adenosine. There are four receptor subtypes (A1, A2A, A2B and A3) which have distinct 
distributions in mammalian tissues (Abbracchio et al, 2007). These receptors often promote 
tissue protection and repair via: increased oxygen supply, preconditioning (a form of 
myocardial protection), modulation of anti-inflammatory effects and stimulation of 
angiogenesis (Linden, 2005). 
P2 receptors are split into two different groups, G-protein coupled receptors (P2Y) and 
ligand gated ion channels (P2X) with 8 P2Y receptors and 7 P2X receptors currently being 
recognised in humans. P2Y receptors generally have seven transmembrane domains, an 
extracellular and an intracellular c-terminal domain. P2X receptors have only two 














Figure 1.1-Stimulation of purinergic receptors: A diagram showing the release of ATP by a cell, via pannexin-1, to stimulate 
extracellular P2X and P2Y receptors, the enzymes which break ATP down to its products and the stimulation of P2Y 
receptors by ADP. Figure taken from Velazquez et al (2014).  The AR receptor is shorthand for adenosine receptors (P1 
receptors). 
Figure 1.1 shows the secretion of ATP by a cell via pannexin-1 which can then stimulate both 
P2X and P2Y receptors on the cell surface. ATP is broken down to ADP (adenosine 
diphosphate) by E-NTDPase via cleavage of a single phosphate group from the molecule. 
ADP can then stimulate P2Y receptors. ADP can also be hydrolysed to produce AMP by E-
NPP and then AMP (adenosine monophosphate) by CD73 to produce adenosine which is 
able to stimulate P1 (AR) receptors (Velazquez et al, 2014). 
 
1.2 P2X Receptors 
P2X receptors are a family of non-selective cation channels, within the P2 purinoreceptor 
group, which are naturally stimulated by ATP. The receptors are each assembled from three 
subunits (P2X1-7) in a homomeric or heteromeric combination (Nicke et al, 1998). P2X7 
appears to be the only subunit which is ‘unable to make heterotrimeric channels’, whilst 
P2X6 in contrast, very rarely makes homomeric channels (Kaczmarek-Hájek  et al, 2012). The 
subunits have a ‘dolphin- like’ shape which consists of head, flippers, dorsal fin and tail 
domains shown in figure 1.2 below. Three subunits join to form a chalice-shaped receptor 
which has three ATP binding sites formed between two adjacent subunits and using 











Figure 1.2-P2X monomer and trimer quaternary structure: A diagram showing, with annotations, the characteristics of a 
P2X monomer signifying the reason for it being referred to as ‘dolphin-like’ (left).  Also, the combination of three of these 
monomers to produce the fully functional receptor, with lengths of the extracellular and transmembrane/intracellular 
domain included, as well as an indication of where the ATP binding sites are situated in the trimer (right). Figures taken 
from work by Young (2010).  
Upon ATP binding to the receptor, there is a conformational change in the three subunits 
which open lateral fenestrations (windows) in the side of the receptor, allowing cations to 
transverse the cell membrane 
The first crystal structure of a P2X receptor was solved by Kawate’s group (Kawate et al, 
2009), who presented the zebrafish P2X4 in its closed state. This has since been improved 
upon via the determination of the x-ray structure for both the closed and ATP bound, open 
channel confirmation for zfP2X. Other P2X receptor structures which have been determined 
include Gulf Coast tick P2X, human P2X3 (hP2X3) and giant panda P2X7 (Karasawa, 2016: 
Kasuya et al, 2016), high-resolution structures of the P2X1, P2X2, P2X5 and P2X6 receptors have 
still not been published. 
The number and position of ligand binding sites on P2X monomers was illusive for a long 
time (Roberts et al, 2006) until these sites were identified for P2X 1-4 using a mutagenesis-
based approach which aimed to find the key residues needed for effective binding (Evans et 
al, 2009: Evans et al 2010). In these studies, the group found that the ligand binding site for 
zfP2X was generally conserved within the family and that there were several key residues. 
The residues which they found to be key were Lys68, Lys70, Arg292, and Lys 309 in the P2X 
primary sequence, which was supported by previous evidence (jiang and Fo, 2000). These 
were found to be important as mutation of these residues led to a significant reduction in 
ATP sensitivity. The non-conserved amino acid residues in the sequence are also important 
as they contribute to the heterogeneity of the receptors. There are three binding sites per 
functional P2X receptor, with these sites said to be at the interface between two adjacent 
subunits. This has been corroborated by studies involving radiolabelled ATP (Jiang et al, 
2011) which bound to the proposed binding cavity and mutagenesis studies which suggest 
that residues from the two different subunits are involved in ligand binding (Wilkinson et al, 




1.3 P2X4 Receptors 
This study will focus on human P2X4 which was first cloned and characterised from the 
human brain in 1997 (Garcia-Guzman et al, 1997). This purinergic receptor is found in many 
tissues including neurons, glandular tissues and endothelial cells. P2X4 is one of the most 
sensitive purinergic receptors, being stimulated at nanomolar concentrations of ATP, which 
makes it 1000-fold more sensitive than P2X7 (Burnstock et al, 2011). The P2X4 receptor has 
been linked to neuropathic and inflammatory pain as well as cardiac function, microglial 
damage and neuronal development disorders (Yang et al, 2004: Yardley et al, 2013). This has 
made it a key therapeutic target for these conditions and so research into this receptor has 
intensified over the last 20 years.  
P2X4 is involved in many processes in the body and plays a key role in neuronal function as 
it is the most widespread P2X receptor in the CNS being expressed in most meurons and 
glial cells (Bo et al, 2003; Stokes et al, 2017). P2X4 is involved in physiological processes in 
the CNS such as neurotransmitter modulation and in the hippocampus the presence of P2X4 
is believed to contribute to synaptic plasticity (Sim et al, 2006). P2X4 along with GABA 
receptors may play a role in the regulation of synaptic signalling (Jo et al, 2011). P2X4 is 
found in an array of epithelial and endothelial cells, performing a wide range of functions. 
This means that disfunction of P2X4 signalling can cause many different effects in different 
tissues leading to various pathophysiological processes. 
P2X4 is known to regulate the effects of alcohol on microglia (Gofman et al, 2014). Alcohol 
perturbs many processes in the brain including phagocytosis, cell migration and 
proliferation (Kumada et al, 2007). In extreme cases alcohol is also known to promote 
apoptosis in microglia (Sakar et al, 2010). These issues can be attributed to Alcohol-induced 
expression of P2X4 on microglial cells. A study in 2011 showed that P2X4 knock out mice 
had a reduction in the detrimental effects of alcohol intake (Wyatt et al, 2014). This receptor 
mediates its role in neuropathic pain via Brain Derived Neurotropic Factor (BDNF). BDNF is 
secreted by microglial cells which are activated by ATP. Inhibitors for BDNF have been 
shown to supress hypersensitivity in several chronic pain models (Masuda et al, 2016) and in 
contrast the direct injection of BDNF into rats has been shown to cause hypersensitivity, 
which is where the immune system reacts extremely to a stimulus, causing pain (Lin et al, 
2014). 
P2X4 is implicated in inflammatory pain as ATP is a pro-inflammatory molecule. This is due 
to it being a signalling molecule which is involved in triggering the inflammatory cascade. 
Chronic inflammatory pain arises due to an immune response which is mounted towards a 
stimulus such as tissue damage, however the pain doesn’t subside even after the damaged 
tissue is repaired (Marchand et al, 2005). The working hypothesis for the role of P2X4 in 
chronic inflammatory pain is that, ATP released from damaged cells stimulates P2X4 
receptors on microglial cells and modulates their function (De Vigrilo et al, 2006: Jarvis et al, 
2010). This causes microglia to produce chemokines, cytokines and neurotrophic factors 
which affect neuronal function, leading to the persistence of the pain sensation (Watkins et 
al, 2001).  
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P2X4 receptors are resident on macrophages and when stimulated can cause a Ca2+ influx 
resulting in the cyclooxygenase (COX)-dependent release of Prostaglandin E2 (PGE2) via p38 
MAPK phosphorylation. PGE2 is an important cytokine in the inflammatory cascade. In 2010 
a group showed that when P2X4 was knocked out in human macrophages, Ca2+ influx was 
significantly reduced (Ullmann et al, 2010). In wild type macrophages, ATP addition resulted 
in a 3-fold increase in PGE2 production by macrophages, but with P2X4 deficient 
macrophages the basal rate of PGE2 production was significantly reduced and addition of 
ATP did not increase PGE2 release. In these P2X4-deficient mice, the receptor was shown to 
mediate both acute and long-term pain, at least in part due to the release of PGE2. The 
arrival of macrophages at the site of a wound is followed by the secretion of PGE2 and other 
cytokines. Initial M1 (pro-inflammatory) macrophages should persist at the site of the 
wound in the early stages of healing but be replaced by M2 (anti-inflammatory) 
macrophages once remodelling of the tissue has begun. When this does not happen and 
there is a prolonged presence of M1 macrophages, there is a prolonged secretion of these 
pro-inflammatory cytokines resulting in persistent inflammation and pain (Schloss et al, 
2018).  
P2X4 also plays a role in rheumatoid arthritis (RA) as it promotes inflammation in the joint 
via activation by ATP. It was shown that targeting the receptor with an antisense RNA led to 
the suppression of several important pro-inflammatory cytokines (li et al, 2014). This result 
suggested that Ca2+ ion influx through P2X4 is necessary for the production of IL-1β, TNF-a 
and IL-6 which are key for RA progression. The receptors role in IL-1β secretion was 
corroborated by a group studying P2X4 activation in osteoarthritis (Fan et al, 2013). 
Effective P2X4 blockade is therefore a perceived therapy for the chronic inflammatory issues 
presented in RA.  
P2X4 has been implicated in chronic neuropathic pain which arises due to nerve damage 
caused by trauma, infection or disease which persists long after the event causing the initial 
damage has healed (Zimmerman et al, 2001). P2X4 was initially shown to be involved in 
neuropathic pain in 2003 (Tsuda et al, 2003) when a group showed that injection of TNP-ATP 
(a P2X4 antagonist) into mice who had suffered peripheral nerve injury reduced mechanical 
allodynia but when PPADS (a non-specific P2X antagonist which doesn’t antagonise rat 
P2X4) was injected, at the same length of time after injury, there was no significant 
reduction in mechanical allodynia. Allodynia is a form of pain which occurs from normally 
non-painful stimuli. This and other papers have proven that P2X4 blockade can reverse the 
effects of allodynia and that when nerve injury occurs there can be a spike in P2X4 
expression, causing this chronic neuropathic pain to begin (Inoue et at,2004: Trang and 
Salter, 2012: Ulmann et al, 2013). These papers suggest that the presence and proliferation 
of P2X4 in spinal microglia are important for inducing and sustaining neuropathic pain after 
peripheral nerve injury. There is evidence that interactions between these glia and neurons 
in the central nervous system are also key in the initiation and maintenance of neuropathic 
pain (Grace et al, 2011). 
A further area of interest for P2X4 research is its role in cardiac function and heart failure. 
Stimulation of the P2X4R has been shown to activate endothelial nitric oxide synthase 
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(eNOS), an enzyme that catalyses the production of Nitric Oxide (NO) which has a cardio-
protective effect on the heart (Yang et al, 2014). NO elicits its protective effect on the heart 
due to its role in reducing blood pressure via vasodilation, preventing hypertension which 
can weaken arteries (leading to myocardial infarctions and strokes). This was shown to be 
the case with mice that had a loss of function for P2X4, these mice were unable to regulate 
vascular tone, resulting in cardiovascular disease (Stokes et al, 2011). The link between 
eNOS and P2X4R was shown to be due to a physical interaction between the receptor and 
the enzyme which results in the production of NO (Yang et al, 2004). In this same paper 
Yang remarked that the blockade of P2X4 in the treatment of diseases such as chronic pain 
could have a detrimental effect on individuals who are under cardiac stress and lead to a 
higher incidence of heart failure due to the reduced NO production. In terms of a 
prospective therapy, a targeted treatment which was able to stimulate P2X4 leading to 
eNOS activation in cardiac myocytes could be beneficial to those at risk of heart failure. 
 
1.4 P2X4 Receptor Pharmacology 
P2X4 receptors have been shown to have a high degree of homology between species. 
Mouse P2X4 has 87% and 94% amino acid sequence homology with its orthologue from 
human and rat respectively (Jones et al, 2000). Human P2X4 has been shown to be 
somewhat sensitive to PPADS and slightly sensitive to suramin (two common P2 
antagonists) but not to the extent of many other P2X receptors such as P2X1 (Soto, 1999; 
Garcia-Guzmann, 1997). ATP and several of its derivative including cytidine triphosphate 
(CTP), 3'-O-(4-Benzoyl)benzoyladenosine 5'-triphosphate (Bz-ATP) and α,β-
Methyleneadenosine 5'-triphosphate (α,β-methylene ATP) (He et al, 2003). All of these 
agonists are non-selective and have a lower potency than ATP. Ivermectin is a positive 
modulator of P2X4. Upon addition of ivermectin, there is an elevation of the maximum 
current achieved and a slowing of the deactivation rate for the receptor, when using a patch 
clamp analysis. These two effects are believed to be mediated by two separate binding sites 
on the receptor with a high affinity site affecting the maximal current and a lower affinity 
site affecting deactivation rate (Priel et al, 2004).  
P2X4 like the other members in the receptor family is made up of 3 subunits, with the 
interactions between these subunits forming the binding pocket for agonists. The ATP 
binding sites are said to be in deep grooves ‘outside of the trimer’ (Kawate, 2009). This is 
believed to be the case because, this region contains 10 highly conserved residues and the 
amino acid composition of this region being compatible with an ATP binding motif (Ennion 
et al, 2000: Roberts et al, 2004). The binding site takes seven residues (K70, K72, T189, L191, 
K193, L217 and I232) from dorsal fin and lower body of one subunit and three (N296, R298, 
and K316) from the head domain and upper body of an adjacent subunit to produce the 
binding pocket (all numbers are from zfP2X4). Each of these residues has a key role in ATP 
recognition and placement in the binding pocket. T189, L191 and I232 interact with the 
adenine moiety and L217 recognises the ribose ring. K70 coordinates the oxygens on the 
phosphate groups of ATP, K193 and N296 mediate receptor interactions with β phosphate 
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groups, whilst K72, R298 and L316 are responsible for coordinating the γ-phosphate groups 
(Chataigneau et al, 2013).  
The binding of only one ATP is not sufficient to activate the receptor but does cause a 
change in the structure, which increases the ease of binding for the second and third ATP 
(Jiang, et al, 2012). There is evidence however, that the binding of only two ATP molecules 
may be sufficient activate P2X receptors (Stelmashenko et al, 2012). The binding of three 
ATP molecules to the three binding pockets of the receptor can activate P2X4, causing a 
conformational change. Mapping of closed and open state confirmations of P2X receptors 
show that there is almost no change to the upper domain of the receptor other than a small 
increase in the pore size at the top of the receptor, although this is still too small to allow 
the passage of ions through a central pathway via the three vestibules in the ectodomain 
(Hattori et al, 2012). The head and dorsal fin domains change confirmation slightly also to 
accommodate the ATP molecule. In the lower body domain however, there is a 
conformational change to the left and right flipper domains which causes the lower domain 
to ‘flex’ outwards, increasing the size of the extracellular vestibule. This flexing provides a 
pathway for ion influx by creating the lateral fenestrations in the sides of the receptor. In 
the transmembrane domain (TM), outward flexing of the lower body causes the TM a-
helices to expand in a spiral-like fashion increasing the pore diameter and allowing the 














Figure 1.3-Open and closed state zfP2X4 channel: A view of the zfP2X4 channel in closed and ATP-bound open states 
parallel to the membrane. The main areas of change in the receptor are annotated to show the ‘flexing’ of the lower body 
domain and how this increases the size of the extracellular vestibule. The binding site of two ATP molecules is shown as 
well as how this causes the ‘Gate’ of this ion channel to open through the separation of the a-helices in the 
transmembrane domain. Figure taken from Wang et al (2016). 
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The confirmation of the P2X4 receptor is key to its function. A group showed that the 
substitution of Tyrosine 315 in the extracellular domain for a cysteine leads to higher pulse 
pressure. This occurs because another cysteine is introduced to a domain which contains 10 
key cysteine residues and may result in the formation of a new disulphide bond, disrupting 
the channel structure (Stokes et al, 2011). This mutation affects the arterial tone as P2X4 
activation causes NO release by endothelial cells (via eNOS) and smooth muscle cell 
relaxation. Therefore, with this mutation in place there is no NO release and a lack of 
smooth muscle relaxation, leading to higher pulse pressure (Cragie et al, 2018; Yang et al, 
2012). 
There are only a few known P2X4 antagonists currently available. These include, paroxetine 
which is a serotonin reuptake inhibitor which is currently used to treat neuropathic pain 
(Toulme, 2010). Paroxetine however does not selectively inhibit P2X4 so will have 
widespread side effects if used solely as an inhibitor for this receptor. Another non-selective 
inhibitor is TNP-ATP which has potency in the low micromolar range but when looking for an 
antagonist which could be used as a possible therapeutic aid for P2X4 related diseases a 
selective antagonist would be preferential.  There are several selective candidates currently 
available such as PSB-12054 which has been shown to have an IC50 value of 189nM and 
good selectivity for P2X4 over other P2X receptor sub types (Hernandez-Olmos et al, 2012). 
PSB-12054 conveys its inhibition allosterically. A second selective antagonist is BX-430 which 
is also allosteric. BX430 was found to have an IC50 of 540nM and is said to be highly 
selective for P2X4 over other P2X receptors with virtually no effect at these other receptors 
(Ase et al, 2015; Yatsumura et al, 2016). A third selective P2X4 antagonist is 5-BDBD. There 
has been debate over the action of 5-BDBD and whether it is an effective selective 
antagonist for P2X4 as is claimed by the various companies which supply it. 
In this project PCR based mutagenesis techniques will be used to identify sites which 
mediate the inhibitory effects of 5-BDBD on the human P2X4 receptor. 
 
1.5 5-BDBD 
5-BDBD (5-(3-Bromophenyl)-1,3-dihydro-2H-Benzofuro[3,2-e]-1,4-diazepin-2-one) is a 
benzofurodiazepine derivative which is selective for P2X4 at low micromolar 
concentrations, with one provider claiming that it ‘exhibits no significant antagonist effects 











Figure 1.4-5-BDBD structure: The chemical structure of 5-BDBD showing the different groups on the molecule which 
may interact with the hP2X4R (Sigma Aldrich, 2019). 
There is debate as to the action of 5-BDBD due to the conflicting evidence, with some 
papers stating that it is a completely competitive antagonist and another stating that it is 
wholly allosteric. The original data which suggested that 5-BDBD acted competitively 
came from 2013 (Balazs et al, 2013) in which the addition of two different concentrations 
of 5-BDBD (2µM and 20µM) resulted in a rightward shift of the ATP concentration 
response curve, without a reduction in the maximal current, which is indicative of a 
competitive inhibitor. This data has been used by several studies since in order to state 
the action of 5-BDBD as an antagonist, (Casati et al, 2011; Wu et al, 2011: Bin Ahmad, 
2018) with several confirming that it has a similar potency to TNP-ATP. The true nature of 5-
BDBD as an antagonist was however disputed in 2017 (Abdelrahman et al, 2017). In this 
paper the group used a radiolabelled P2X agonist [35S]ATPyS, which the cells were pre-
treated with so that the agonist could bind to the receptor before the antagonist was 
added. They used TNP-ATP, paroxetine and 5-BDBD, aiming to see which of these could 
displace the radiolabelled ATP. It was shown that TNP-ATP, [35S]ATPyS and 5-BDBD all had a 
similar potency in this project. TNP-ATP was able to displace the [35S]ATPyS whilst 5-BDBD 
and paroxetine (a known allosteric inhibitor) were not. 5-BDBD slightly reduced radio-ligand 
binding at high concentrations, although not significantly. This suggests that 5-BDBD does 
not competitively inhibit P2X4 because at a high enough concentration a competitive 
antagonist would displace an agonist due to the dynamic relationship between an agonist 
and its receptor. This is especially true if the agonist and antagonist have a similar potency. 
Since TNP-ATP was shown to be able to displace the radiolabelled ATP and 5-BDBD being 
remarked to have a similar potency to TNP-ATP, this would go to show that 5-BDBD must 
bind allosterically as the group concluded. There is also evidence from this paper that 5-
BDBD is most potent at human P2X4 receptors with its potency being 6-fold less at mouse 
P2X4 and 10-fold lower for rat. This group does however seem to stand alone in its belief 
that 5-BDBD acts non-competitively, with much of the literature stating the opposite due to 
being influenced by the 2013 study. 
5-BDBD has been used in several studies already as a means of blocking P2X4 activity such 
as, 50µM 5-BDBD being applied to gingival keratinocyte as a means to explain the role of the 
receptor in reactive oxygen species production (Hung et al, 2013). Another study used 10µM 
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of 5-BDBD to show that P2X4 is the main purinergic receptor which is involved in 
prechondrogenic condensation. Prechondrogenic condensation is the formation of a 
cartilaginous template which is replaced by bone in the early stages of embryonic limb 
development, it is said to be one of the ‘most critical processes in skeletal development’ 
(Kwon, 2012). 
5-BDBD is believed to be selective for P2X4 with its antagonism being tested at P2X1, P2X3, 
P2X4, P2X7 and two P2X2 functional splice receptors (a and b) (Coddou et al, 2019). In this 
study they found that for P2X7 and both P2X2 variants there was no significant inhibition of 
response when 10µM of 5-BDBD was added for a pre-incubation of 2 minutes. The group 
did find that 5-BDBD caused a significant reduction in the current amplitude, when 
performing a patch-clamp assay, for both P2X1 and P2X3 with 12.7% and 35.9% reductions 
respectively. The inhibition for P2X4 was found to be 83.2%, with the group concluding that 
5-BDBD can be used to discriminate between P2X4 and the other receptors used.  
Coddou’s study was however undertaken using P2X receptors from rats for which 5-BDBD 
has a lower potency than humans. Another selective P2X4 antagonist (BX430) has also 
shown species-dependent differences in potency, being a potent antagonist at hP2X4 but 
having no effect on the mouse and rat orthologues (Ase et al, 2015). There is however no 
corresponding study for 5-BDBD currently. The only evidence which has been presented to 
show that there may be species differences was published in 2011 (Vavra et al, 2011). In this 
study the group applied 5-BDBD to rat brain slices in 3µM and 30µM doses and saw that it 
failed to inhibit the ATP induced current when performing a patch clamp analysis. In the 
study they hypothesise that 5-BDBD may not be effective on endogenous heteromeric P2X4 
receptors. This may be the case, but It could conversely be due to the species difference. 
P2X2 will be used in this project to test the selectivity of 5-BDBD for P2X4 due to it not being 
significantly inhibited by 5-BDBD for either splice variant tested (Coddou et al, 2019). The 
selectivity of the inhibitor for P2X4 will be determined by comparing the IC50 value of 5-
BDBD for these two receptors in order to understand its potency for each. If P2X2 is 
significantly less sensitive to 5-BDBD than hP2X4 the aim of this project is to try and locate 
the sites on hP2X4 which are important for the inhibitory effects of 5-BDBD. This will be 
attempted by replacing 10 amino acid stretches of the hP2X4 extracellular domain with 
aligned stretches from P2X2 to make P2X4 chimeric receptors. This should result in there 
being discrepancies in 5-BDBD efficacy between the different mutants, showing which 
regions of the receptor may be important in 5-BDBD action.  
The PCR-based mutagenesis protocol to be used is similar to that which previously found 
the ATP binding site for zebrafish P2X4 (Grutter et al, 2013) and human P2X1 (Evans et al, 
2007). Another group (Ase et al, 2019) have produced point mutants in several species using 
a PCR mutagenesis protocol in order to elucidate where BX430 may interact with P2X4. In 
order to do this, they aligned the sequences for rat, zebrafish and human P2X4 receptors. In 
this paper, the group identified a single hydrophobic residue (Ile 312) which determined 
inhibition of P2X4 by BX430, when this residue was substituted with a threonine or glycine 
residue, sensitivity to BX430 was lost. This also explained the selectivity of BX430 for human 
P2X4 over the rat and mouse variants as the isoleucine at this position is substituted for a 
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threonine residue. This paper also suggests that the binding pocket for BX430 is conserved 
among the P2X family and the presence of the Isoleucine at position 312 allows for 
inhibition of the receptor. It will be interesting to understand whether 5-BDBD interacts 
with the receptor in the same region (the potential binding pocket) or at a different site 
entirely. 
When important regions of the receptor are found, smaller changes may be made within 
these regions in order to find specific residues which may be involved in 5-BDBD action. 
 
1.6 Aims and Hypotheses 
In this study the first aim is to characterise the action of 5-BDBD including its mechanism of 
antagonism at human P2X4, be that via competitive, non-competitive or mixed modal 
means. This will be attempted by producing ATP d concentration response curves with 
increasing concentrations of 5-BDBD present. The concentrations that will be tested will be 
1µM to 30µM. From the data collected the EC50 value and maximum response achieved at 
each 5-BDBD concentration can be derived and compared. A competitive antagonist will 
cause an increase in EC50 value with increasing 5-BDBD concentration and a rightward shift 
of the ATP concentration response curve. A non-competitive antagonist will cause a 
reduction in the maximal response achieved with increasing antagonist concentration.   
Once the action of 5-BDBD has been determined the next aim will be to find where 5-BDBD 
may interact with the receptor and discovering whether it has one or multiple binding sites. 
This will be attempted using PCR based mutagenesis in order to highlight regions on the 
receptor which may be important for 5-BDBD action and then focusing in on particular 
regions of interest to see if residues within these regions could be linked to 5-BDBD action.  
The final aim will be to present the residues which may be involved in the inhibition of P2X4 
by 5-BDBD via showing that mutations to these residues causes a significant reduction in the 












Chapter 2: Materials and Methods 
2.1 Tissue Culture 
2.1.1 Passaging 
In this project 1321N1 cells were used, which is a human astrocytoma cell line that was 
isolated in 1972 and is often used as a model for neurological diseases. These cells were 
chosen as they are devoid of endogenous purinergic receptors (Martinez et al, 2016). 
Therefore, there was no response to ATP for blank (untransfected/parental) 1321N1 cells. 
This means that when performing transient transfections, there could be confidence that 
any response above the background level was elicited due to the receptor which had been 
transfected. 
Two distinct 1321N1cell lines were used in this study, the untransfected (parental/blank) 
cell line and the cell line stably expressing hP2X4. The stable cell line was produced via 
lentiviral transduction of 1321N1 cells using polybrene reagent (Sigma-Aldrich) which 
helped to increase the efficiency of gene transfer. The lentiviral particles were produced 
using co-transfection with 3 plasmids (lentiviral vector containing the transgene, psPAX2 
with a CAG promoter and pMD2.G which encodes the envelope glycoprotein). The cells 
were sorted based on their P2X4 expression using fluorescence activated cell sorting (which 
identified the mCherry which was also on the plasmid, introduced into the cells) and a cell 
line highly expressing P2X4 was selected. Clonal cell lines were produced from this initial line 
based on their Ca2+ response and the H8 cell line was selected for this project based on it 
providing a medial but robust Ca2+ response. 
Both cell lines were cultured using Dulbecco’s Modified Eagles Media (DMEM; Lonza) 
containing L-glutamine (0.6g/L) which is an essential amino acid for cell growth. 10% (v/v) 
Foetal Bovine Serum (FBS; HyCloneTM) which is a source of nutrients for the cells and 1% 
(v/v) Penicillin/streptomycin (containing 50U/ml of penicillin and 50µg/ml of streptomycin; 
GibcoTM), which was used to reduce the risk of the media becoming infected, were added to 
4.5g/L DMEM. 
The cells were maintained in ventilated T75 flasks (Thermo Fisher Scientific) which were 
kept in a 5% CO2 incubator at 37°C as these were the optimal conditions for cell growth. 
When 70-80% confluency had been reached, the cells were washed with 3ml of phosphate 
buffered solution (PBS; Lonza) and then treated with 3 ml of trypsin (0.25% Trypsin/0.2% 
thylenediaminetetraacetic acid (EDTA) ; Lonza) to sever the cell-cell and cell-plastic 
adhesions, being returned to the incubator for 5 minutes. The flask was gently tapped to 
ensure detachment, the detached cells were added to 3ml of media (to stop the enzymatic 
action of the trypsin) and centrifuged at 1500 rpm for 5 minutes. The supernatant was 
discarded and the pellet resuspended in 3-5ml of fresh media. The cells were counted using 
a haemocytometer (to calculate the cells/ml) and a cell solution was made up to the specific 
density required on the sterile 96 well plates. If the cells were not to be plated, they were 
passaged, returned to a new T75 flask and placed in the incubator again. These cells were 
seeded at 50,000 cells/ml. The cells were only passaged up to 20 times before new cells 
were retrieved from the liquid nitrogen store. All solutions used were pre-warmed to 37°C 





For non-transfection plates, cells were seeded the night before they were to be used at 
35,000 cells/ml. The transfection plates were seeded at 12,500 cells/ml, three days before 
they were to be used with the transfection happening the day after seeding and there being 
two days of incubation between transfection and running. This extended period is due to 
transfection reagents and DNA being toxic to the cells so some cells will die in this stage, 
meaning it takes longer to reach confluency. Both plate types contained deionised water in 




When there was a surplus of early passage (1-8) cells for either the untransfected or stably 
transfected lines, these cells were stored in liquid nitrogen for future use. When the excess 
cells had been passaged and a cell solution produced, this solution was aliquoted into falcon 
tubes of 1x106 cells. These falcon tubes were centrifuged at 1500 rpm for 5 minutes and the 
supernatant was discarded. The resulting pellet was resuspended in 900µl of media 
containing 70% DMEM and 30% FBS. This solution was transferred to a cryovial and had 
100µl of sterile 100% DMSO added to it, which prevented crystals from forming 
intracellularly when freezing. This produced a final solution which was 1x106 cells/ml. The 
vials were moved to a MrFrostyTM (Thermo Scientific) to slowly regulate temperature 
reduction and stored at -80°C for 24 hours. After this period the vials were moved to the 
Liquid nitrogen store for long term storage. 
When the cells were needed, they were removed from the liquid nitrogen store and thawed 
in a water bath at 37°C until nearly all of the solution had thawed. The solution was then 
quickly diluted in 4ml of fresh media and centrifuged at 1500 rpm for 5 minutes. The 
supernatant was decanted and the pellet resuspended in 1ml of media. The new cell 
solution was then added to a T25 flask containing 4ml of fresh media. The cells were placed 
in a 5% CO2 incubator at 37°C for 24-48 hours, depending on growth rates and when they 
approached confluency, the cells were passaged in the fashion described in 2.1.1 and either 
seeded in a T75 or on a 96-well plate. 
2.1.4 Salt Buffered Saline and Loading Buffer preparation 
Salt buffered saline (SBS) was prepared in deionised water and contained the following in 
the given concentrations: sodium chloride (NaCl) 130mM, potassium chloride (KCl) 5mM, D-
(+)-glucose 8mM, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; Fisher 
Scientific) 10mM, magnesium chloride (MgCl2) 1.2 mM and calcium chloride (CaCl2) 1.5mM. 
The solution was titrated to pH 7.4 in 1L of SBS using 10mM sodium hydroxide (NaOH). 
To produce loading buffer (LB), pluronic acid was added to 200ml of SBS (0.01% (w/v)). 
Pluronic acid helps to stabilise the cell membrane preventing shearing upon Fura-2 entry 
into the cells, reducing losses in cell viability (Tharmalingam et al, 2008). The supplier of all 





2.1.5 Plate preparation 
Stably expressing cells were seeded at 35,000 cells/well and incubated at 37°C in 5% CO2 for 
24 hours before running. 
Transiently transfected (parental) cells were seeded at 12,500 cells/well, being incubated 
for 96 hours (with transfection after 24 hours).   
The parental cell line was seeded at a lower density as transfection is made harder when 
cells approach confluency and this allowed cells  to have a longer period of growth to 
recover after transfection. 
To prepare for the Flexstation, the media in the wells was removed and the cells were 
washed with SBS, to remove dead cells and any remaining media. Loading buffer with 2µM 
Fura-2 (Abcam) is then added to the wells (200µl per well) and incubated for one hour, to 
allow time for Fura-2 to enter the cells and have its AM domain cleaved. 
The loading buffer was removed, the cells were washed with 200µl of SBS twice and finally 
199µl (5-BDBD protocol) or 200µl (non 5-BDBD protocol) of SBS was added to the wells. If 
there was to be 5-BDBD used, 1µl of 5-BDBD at a given concentration (produced by diluting 
a frozen 10mM stock of 5-BDBD made by dissolving powdered 5-BDBD in 100% DMSO) or 
100% DMSO was added to each well and the plate was incubated for 30 minutes before 
running. This resulted in a final 5-BDBD or DMSO concentration of 0.05% in each well. If 5-
BDBD was not in the protocol, the plate could be run immediately. The plates were wrapped 
in tin foil for incubations and all work is to be done in the dark, in order to protect Fura-2 
from photo-bleaching. 
ATP was made by dissolving powdered ATP in SBS to make a 10mM stock. A new stock must 
be made for each plate which is run, this is to reduce the chance of a mistake on one plate 
being carried over to further plates. From the stock solution the highest concentrations to 
be used were produced by diluting the stock in SBS. From these the rest of the 
concentrations used on the plate were produced by serial dilution. If one ATP concentration 
was to be used for the whole plate, a stock solution was produced from the 10mM stock by 
diluting in SBS. 70-80µl of the relevant ATP concentrations were pipetted into a 96-well 
round bottom plate in the corresponding position of the well which they were to be added 
to on the flat bottom plate containing the cells. All solutions were pre-warmed to 37°C in a 
5% CO2 incubator. 
 
2.2 Transient Transfection of P2X4 Protocol 
Transfection is a process by which exogenous DNA is introduced into a cell and incorporated 
into its genome. In this study the exogenous DNA encoded the hP2X4R gene  and gave the 
parental cell line the ability to express P2X4.  
The full transfection protocol took four days from seeding to running the plate. On the first 
day 12,500 cells were seeded per well after being passaged and counted. The plate was left 
in a 5% CO2 incubator over night at 37°C. On day two, the media in the wells was removed 
and replaced with 200µl of fresh media, this was to remove dead cells which failed to 
adhere to the bottom of the well. Stock solutions of DNA and Lipofectamine 2000 were 
made by diluting both in optimem media (Thermo Fisher Scientific) in order to reach a 
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concentration twice that of what was needed on the plate (300ng/well of DNA and 
0.5µl/well of lipofectamine on the plate). The DNA and Lipofectamine 2000 stock solutions 
were combined to produce a master mix (halving their concentrations). The master mix was 
incubated at room temperature for 5 minutes to allow the Lipofectamine to bind to the 
DNA. 10µl of the master mix was added to each well and the plate was returned to the 
incubator for two further days. The plate was run using the method for 5-BDBD addition. 
2.3 DNA Extraction 
1-2µl of a frozen glycerol stock of E. coli was pipetted onto a 20ml agar plate (fisher 
Scientific) made with 20µl of Ampicillin (100 µg/ml; Sigma Aldrich) included (which the E. 
Coli had a resistance gene for). The agar and ampicillin were combined and swirled for 2-3 
minutes to ensure homogeneity of ampicillin in the agar before use. The plates were 
incubated for 16 hours at 37°C in a 5% CO2 incubator. One colony was chosen from the agar 
plate and place into a universal tube containing 12ml of LB broth (Fisher Scientific) and 
0.001% Ampicillin (v/v). The universal tubes were incubated for 16 hours in a rotating 
incubator (225 rpm) to prevent the cells from sedimenting at the bottom of the tube. The 
universal tubes were centrifuged at 2000 rpm for 20 minutes, the cells were ligated and the 
DNA collected and purified by following the instructions for the omega ENZA mini-prep kit 
(omega bio tek). The extracted DNA was tested for purity and concentration using a 
Nanodrop 2000 spectrophotometer (Thermo Fisher) before use. 
2.4 Mutagenesis  
All mutagenesis steps were performed using the Q5® Site-Directed Mutagenesis KitTM (New 
England biolabs). 
Both LB broth and LB Agar were produced by 40g of powdered Agar (Fisher Scientific and 
20g of powdered LB broth (Fisher Scientific) respectively being dissolved in 1L of deionised 
water and autoclaved to ensure homogeneity. 
 
2.4.1 Designing Primers 
All primers used within this project for the production of chimeras, were produced using the 
New England BioLabs online design software, NEBaseChangerTM (NEBaseChanger, 2019). 
The primers were purchased from Thermo Fisher Scientific and came premade in 10µM 
stocks. These Primers were stored at -20°C until they were to be used. 
The primers produced using this method and utilised in this project are stated below: 
Name (F/R) Oligo (Uppercase = target-specific primer) Len % GC Tm Ta * 
Q5SDM_6/29/2019_F gtggcggattatgtgATACCAGCTCAGGAGGAA 33 52 62°C 
60°C 
Q5SDM_6/29/2019_R atcccagatccggtgTCCAAGTTTAGAAGTGTTGG 35 49 59°C 







 Firstly, the DNA was amplified using polymerase chain reaction (PCR) which cycled different 
temperatures for differing periods  which allowed  the primers to insert the chimeric DNA 
into the wildtype plasmid and for the amplification of this plasmid. Each reaction was 
performed by combining 1µl of wildtype P2X4 plasmid (20ng/µl), 1.25µl of both the forward 
and reverse primers (10µM stock solutions), 9µl of nuclease-free water and 12.5µl of Q5 hot 
start high-fidelity master mix in a PCR tube. 
Table 1- PCR Methods: The stages involved in the PCR process with temperatures and the time each step takes delineated. 
There were 25 cycles in the amplification steps which followed a cycle of denaturation, annealing and then extension 
moving downwards. There were two variables which were specific to this project the annealing temperature  could change 
within this range based on the size of the primers and secondly the extension time  was calculated by 30 seconds 









The PCR was performed in a thermocycler (Verti) and the PCR product was stored at -20°C 
until it was to be used in the KLD reaction. 
 
2.4.3 Kinase, Lipase and Dpnl Reaction 
The Kinase, Lipase and Dpnl (KLD) reaction took 1 µl of the PCR product and added 5µl of KLD 
reaction buffer, 1µl KLD enzyme mix and 3µl of nuclease free water in a fresh Eppendorf 
tube. The solution was incubated at room temperature for 30 minutes. 
 
2.4.4 Transformation 
5µl of the KLD reaction solution was added to 50µl of chemically competent E. coli cells, 
which were thawed on ice for 5 minutes prior to KLD solution addition. The cells were 
incubated for 30 minutes on ice, then heat shocked at 42°C for 30 seconds (to induce 
competency and allow the plasmid to enter the cells) and incubated on ice for 5 minutes. 
450µl of super optimal broth with catabolite repression (SOC) media was added to the cells 
and they were incubated in a rotating incubator (125rpm) at 37°C for 1 hour. 
Finally, 50 and 200µl of the solution was pipetted onto agar selection plates and incubated 
at 37°C in 5% CO2 for 16 hours. 
 












72°C 5 minutes 
Final Extension 72°C 2 minutes 
Hold 4°C ∞ 
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2.4.5 DNA Isolation and Testing 
A colony was selected from the agar plate and added to a universal tube containing 12ml of 
LB broth and 0.1% ampicillin (v/v). The tube was incubated at 37°C in a rotating incubator 
(225 rpm) for 16 hours. The DNA was extracted following the omega ENZA mini-prep kit and 
Nanodrop tested for purity. The DNA was then diluted to 100ng/µl and 5µl was sent to 
Source Bioscience for sequence analysis. When the sequence returned it is checked using 
Clustal Omega (EBI) and Sequence Manipulation Suite (Bioinformatics.org) to ensure that 
the correct mutation had been made and that there were no other mutations which had  
occurred in the amino acid code. Glycerol stocks of the E. coli were produced by taking 
1.2ml from the overnight culture in the universal tube and adding it to 300µl of glycerol in a 
1.5ml Eppendorf tube. These stocks were stored at -20°C until needed. 
 
2.5 Flexstation Protocols 
In this study a Flexstation III was used running on the program SoftMax Pro. The Flexstation 
used this program in order to present the Fura-2 fluorescence graphically over the period of 
observation for each well (250 seconds). The Flexstation pipetted 50µl of agonist into each 
well after 20 seconds of the assay and the change in intracellular free Ca2+ concentration 
was recorded for the remainder of the time. The change in intracellular Ca2+ was signified by 
a change in Fura-2 fluorescence ratio (340:380nm).  
Fura-2AM  contains an acetoxymethyl ester group attached which allows the molecule to 
enter the cell. Once inside the cell the AM group is cleaved by cellular esterases, rendering 
the Fura-2 unable to exit the cell. Fura-2 binds to intracellular free Ca2+ and fluoresces at 3 
distinct wavelengths: 510nm, 340nm and 380nm with 510nm fluorescence being constant 
(MacDermott et al, 1994).  When not bound to Ca2+ Fura-2 fluoresces at 380nm but when it 
is bound to Ca2+ it fluoresces at 340nM. The ratio of bound to non-bound Fura-2 can be used 
to quantify the concentration of intracellular Ca2+ as Fura-2  naturally binds to free 
intracellular Ca2+ with a high affinity (Paredes et al, 2008). This  meant that the 
concentration of Ca2+ bound Fura-2 was a good indicator for the concentration of 
intracellular Ca2+ in general. The concentration of intracellular Ca2+ changing was therefore  
used as an indicator for cation movement in general as P2X4 is a non-selective cation 
channel. This ratio of 340nm to 380nm  was shown on the SoftMax program as an ‘F ratio’ 
which  allowed for comparison between different conditions (such as changes in ATP or 5-
BDBD concentration). 
 
2.6 Data Analysis 
The Data was collected by the SoftMax Pro program in the form of the peak F ratio achieved 
in each assay and exported to excel. The data had the blank response removed, this was the 
basal response which was caused by small fluctuation in F ratio, resulting from the dynamic 
relationship between Fura-2 and the intracellular Ca2+ before ATP addition. The blank 
response was calculated from 3 or more wells on each plate which contained cells at the 
same density as the rest of the plate but had 50 µl of SBS added to them rather than 50µl of 
agonist. The data was then normalised to the concentration giving maximal response or a 
control on each plate. An average of the repeats on each plate, for each concentration, are 
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taken and the data from the five plates are amalgamated in Origin student pro 2018 
software (Origin Labs).  
All data was presented as a mean with standard error and on each plate there was at least a 
triplicate for every data point. The n number refers to the number of individual plates which 
were repeated for each data point on a graph.  
Many of the graphs were fitted with a concentration response curve using the Hill1 equation 
which aided in the derivation of EC50 (agonist concentration needed for a half maximal 
response) and IC50 (antagonist concentration needed for a half maximal response 
reduction) values. The Hill equation was used to show the degree of cooperation between a 
receptor and its ligand, allowing the quantification of this interaction via production of the 
hill coefficient. In this project a modified version was used (called Hill1 on origin labs) where 
Vmax is replaced by Start + (End – Start) in the equation. This provides the equation with 
offset and fixes the n number which is variable in the standard Hill equation. 
Hill1:   
In this equation, k denotes the Michaelis constant and n denotes the number of cooperative 
sites. 
T-tests or one-way ANOVA statistical analyses were performed if the data was normally 
distributed using a Shapiro-Wilk test and had equal variance using a Levene test. For data 
sets which were not normally distributed or had unequal variance a Kruskal-Wallis ANOVA 
















Chapter 3: Results 
3.1 Transfection Protocol 
When trying to find an efficient protocol for transfecting 1321N1 cells there were four 
candidate transfection reagents in contention, three of which had been previously shown to 
provide adequate transfection (Marucci et al, 2011). The transfection reagents tested were 
FuGene, Polyfect, Lipofectamine and X-treme gene. Each reagent was tested at a range of 
DNA and reagent concentrations to try and find the optimal conditions for transfection 
using that specific reagent before comparisons between them were made. 
Polyfect and FuGene were eliminated from contention due to the inconsistency of 
transfection and both giving a low response when stimulated with maximum ATP (30µM). 
 
  
Figure 3.1-Polyfect and FuGene transfection reagent scan: Two graphs showing the peak response elicited by 30µM ATP 
for each tested combination of transfection reagent and DNA. The left diagram (A) shows the data for Polyfect and the 
right (B) shows FuGene. Both graphs have the blank response included for reference (n=3). The x axis shows a ratio of DNA 
to the reagent. 
Figure 3.1 shows that Polyfect and FuGene were both unsuitable to be used as the 
transfection reagent for this study as they both failed to elicit a response which was 
significantly different from the background (blank). The highest F ratio achieved was 0.21 for 
Polyfect and 0.17 for FuGene which would not be sufficient when undertaking the PCR-
based mutagenesis studies. This was due to the need for a robust response which could 
provide a discernible difference between inhibition with 5-BDBD and a non-inhibited 

















Figure 3.2-X-treme Gene transfection reagent scan: A graph showing the calcium response elicited by 30µM ATP at several 
different conditions for X-treme Gene. Those concentrations which produced a response significantly different (p<0.05) 
from the control are marked with an asterisk (n=3). The x axis shows a ratio of DNA to transfection reagent. 
The next reagent tested was X-treme Gene which was more successful, having three 
separate concentrations which were significantly different from the control. The best of the 
concentrations tested for this reagent was 0.3µL of reagent and 150ng per well of DNA 
which gave an F ratio response of 0.24 which was higher than for the previous two reagents 











Figure 3.3-Lipofectamine transfection reagent scan: A graph showing the response elicited by 30µM ATP on cells 
transfected with varying ratios of DNA to Lipofectamine transfection reagent. The ratios which produced a response 
significantly different (p<0.05) from the control were denoted with an asterisk (n=3).  
The final reagent tested was Lipofectamine which produced four conditions that were 
significantly higher than the control response. Of these the largest response was elicited by 
300ng of DNA and 0.5µl of Lipofectamine per well. The response on average for this 
condition was 0.36 which was higher than 0.17, 0.21 and 0.24 achieved for the other 
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reagents. Lipofectamine at this concentration ratio was therefore chosen for the proceeding 
transfection protocol. 
3.2 ATP Concentration Response 
An ATP concentration response curve was produced for both hP2X4 and hP2X2. Both 












Figure 3.4-hP2X4 ATP concentration response curve: A graph showing the normalised peak response of human P2X4 to 
ATP concentrations between 10nM and 300µM. The data is normalised to the maximal ATP concentration. The curve has 
been fitted with the Hill1 equation in order to determine an EC50 (n=5). 
Figure 3.4 shows that the data follows a sigmoidal fit with the curve plateauing at a maximal 
concentration of 30µM. Using the Hill equation an EC50 value of 379.80 ± 98.96nM was 
derived from the graph. It was however said to be 7.4 ± 0.5 μM in the literature (Soto et al, 
1996; Garcia-Guzman et al, 1997) which was significantly different from the potency found in this 
assay. For concentrations higher than 30µM there was a reduction in response measured by 
the Flexstation.  This was due to desensitisation of the receptor to ATP at high 


















Figure 3.5-hP2X2 ATP concentration response curve: A graph showing the normalised peak response of hP2X2 stably 
expressed in 1321N1 cells. The receptors were stimulated with ATP concentrations between 10nM and 300 µM. The data 
was normalised to the maximal response and had a sigmoidal fit added to it using the Hill1 equation in origin labs (n=5). 
Figure 3.5 also shows a common sigmoidal fit with a plateau at the lowest and highest 
concentrations and a characteristic rapid increase between 100nM and 3µM. The EC50 
derived from this graph was 1µM, which was in line with that previously found for P2X2 
(North et al, 2009). When comparing the EC50 values for the five repeats of P2X2 and P2X4 
the two receptors were shown to be significantly different, with a kruskal-wallis post-hoc 
analysis showing that P2X2 had a significantly higher EC50 value. Another difference 
between the two receptors was the lack of desensitisation at P2X2 with the highest ATP 
concentrations not causing a reduction in response like was seen for P2X4. In figure 3.5 
there was a high degree of error at 300nM which is common in the rapidly increasing phase 
of a sigmoidal curve due to the variation in EC50 position between the repeats meaning that 














3.3 IC50 Curve Derivation  
Next an IC50 curve was derived for each of the receptors (P2X2 and P2X4) to determine 











Figure 3.6-hP2X4 IC50 curve: A graph showing the response of P2X4 expressing cells to increasing concentrations of 5-
BDBD between 300pM and 50µM when stimulated with 500nM ATP. The graph is fit with a Hill1 equation in order to find 
the IC50 value. The points are all plotted with their standard error (n=5). 
In figure 3.6 you can see that with increasing concentrations of 5-BDBD after 30nM there 
was a decrease in the normalised response of P2X4 to ATP. This reduction begins to plateau 
at 10 µM. At the low nanomolar concentrations of 5-BDBD there is a plateau at around 
100% of the normalised response. The IC50 value found for this data set was at 873.9nM 
















Figure 3.7-hP2X2 IC50 curve: A curve showing the change in response of P2X2 receptors in the presence of increasing 5-
BDBD concentrations from 10nM to 30µM. The cells were stimulated with 1µM ATP.  The points are all depicted with 
standard error (n=5). 
Figure 3.7 shows that with increasing concentrations of 5-BDBD there was no pattern 
signifying a reduction in ATP response. This was confirmed when performing a Kruskal-
Wallis non-parametric analysis on the data which showed that no concentration of 5-BDBD 
used was significantly different from another concentration in the study. Analysis also 
showed that there was no significant difference between ATP and any of the concentrations 
tested for. There was a reduction in response at 30µM, but it was not statistically significant, 
possibly due to the high error at this concentration. This lack of response reduction differs 
from hP2X4 as the response was approximately 11.9% of maximal response at 10µM 
compared to 86.3% for P2X2. An attempt was made to fit a Hill equation to the graph but an 
























Figure 3.8-20µM 5-BDBD trace for hP2X4: A graph of representative traces to show the difference between a Flexstation 
trace without 5-BDBD being added to the cells (red) and when 20µM is present (black). Each of the traces had 30µM of ATP 
added after 20 seconds of the assay. The stably transfected hP2X4 cell line was used (n=1).  
Figure 3.8 above shows a representative ATP concentration response trace with 30µM of 
ATP added in the presence and absence of 5-BDBD (20µM). This gives a clear indication of 
the inhibitory ability of 5-BDBD due to its reduction of the peak F ratio achieved and the 
change in shape of the trace in its presence. The peak value achieved on a trace was what 
was analysed to signify any changes which have occurred when changing ATP or 5-BDBD 
concentration in an assay. It can be seen by the change in shape of the trace that 5-BDBD 
not only reduces the maximum response seen (a reduction to 47.35% of the red trace), but 




















































Figure 3.9-ATP does response in the presence for 5-BDBD: Graphs showing an ATP concentration response curve with 
various concentrations of 5-BDBD. The data was all normalised to an ATP control (30µM) and the graphs were fit with a 
Hill1 Equation. A) 1µM B) 3µM C) 5µM D) 10µM E) 20µM F) 30µM. Each point has its standard error included (n=5). 
In order to see how different 5-BDBD concentrations affect hP2X4, 1321N1 cells expressing 
this receptor were subjected to 6 different concentrations of 5-BDBD (1µM, 3µM, 5µM, 
10µM, 20µM and 30µM). All of the data was normalised to max ATP with no 5-BDBD added 
to the cells (30µM), which were included on each plate as a control. 1µM gave a higher 
maximum response than was seen for the ATP control with 104.0 ± 5.8% and 3µM had a 
very similar maximal response to the ATP control at 99 ± 4.6%. When conducting a Kruskal-
Wallis ANOVA, these concentrations were not significantly different from the control. The 
EC50 values for these two concentrations were 3.1 ± 0.5µM and 3.7 ± 1.4µM as opposed to 
the 0.4 ± 0.1µM for the ATP concentration response without 5-BDBD. Again however, these 
were not significantly different from ATP. For 3µM and beyond the concentration of ATP 
which gives the maximal response has moved from 30µM (which it was for 1µM and the 
control) to 100µM where it stays for the remainder of the 5-BDBD concentrations. For 5µM 
of 5-BDBD there was a reduction seen in the maximal response to 75.9 ± 5.2% of the 
control. The EC50 for this concentration was 2.8 ± 0.6µM however again these were not 
significantly different from the control values. For 10µM the maximal response given was 
70.9 ± 8.4% which was not significantly different. For the EC50 on the other hand, the value 
of 5.8 ± 1µM was significantly different from the control (p=0.014). This tells us that there 
has been a significant rightward shift of the curve at this concentration. At 20µM there was 
the first significant reduction in the maxima for the concentrations tested with the 
maximum response falling to 48.1 ± 4.6% (p=0.022). The EC50 value was also significantly 
different from ATP again at 6.0 ± 1.3µM (p=0.009). For the final concentration of 30µM 
there was again a significant reduction in the maxima and increase in the EC50 value from 
the control at 41 ±3.1% (p=0.018) and 7.2 ± 1µM (p=6x10-4) respectively.  
 
Table 2-5-BDBD concentration dependent response: The comparison of different 5-BDBD Concentrations to an ATP 





Table 2 shows the amalgamation of the EC50 and maximal response data for the different 
inhibitor concentrations including the significance from the control and the standard errors 
at each concentration. There are 3 concentrations which show a significant increase in the 
EC50 value (10, 20 and 30µM) and two showing a significant reduction in the maximum 
response (20 and 30µM). As you can see at all 5-BDBD concentrations (although it may not 
be immediately obvious for 20µM) there was a desensitisation of the receptor at the highest 
concentrations of ATP meaning that there can be confidence in having achieved the 
maximal response possible for each of the 5-BDBD concentrations. 
 
Figure 3.10-5-BDBD ATP concentration response curves on one graph: The amalgamation of data for each of the 5-BDBD 
concentrations tested and the ATP concentration response which they were compared to. Each of the curves was fitted 
using the Hill1 equation in order to find the EC50 value for each curve. All the 5-BDBD concentrations were tested against 
ATP concentrations from 100nM to 500µM. The ATP concentration response curve includes ATP concentrations from 30nM 
to 300µM (n=5).  
Figure 3.10 aligns all the data with curves from each of the 5-BDBD concentrations tested 
for and the control ATP concentration response curve. This figure helps to visualise the 
changes in maxima and EC50 value which have been stated as the curves shift to the right 
when EC50 significantly increases and the height of the curve decreases as the maxima 
begins to be significantly reduced. As the graph shows, with increasing 5-BDBD 
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concentration there are two clear trends of right on the X axis and down on the Y axis 
signifying the decreasing potency of ATP for the receptor and the reduction in efficacy 
respectively. 
3.6 P2X4 Functional Mutant Scan of the Receptor 
Due to previous work with P2X4 antagonists which had been conducted in our lab, there 
was a pre-existing library of chimeric receptors which had 10 amino acid substitutions to the 
extracellular domain. These stretches of amino acids had been replaced with aligned 
sequences from P2X2, which section 3.3 showed was relatively insensitive to 5-BDBD.  
There were 29 possible mutants that could be made for the receptor encompassing the 
whole of the extracellular from 55-338 in the primary sequence. Of the mutants tested 21 
were functional, meaning that they gave a response to ATP and one mutant was found to 
have the same sequence of 10 amino acids in both P2X2 and P2X4 when aligned. 
These functional mutants were challenged with 30µM of ATP and 20µM of 5-BDBD. There 
were five wells on each plate with only ATP and 5 wells with ATP and 5-BDBD for each of the 
mutant receptors. The inhibition in response to 5-BDBD addition was then calculated and 












Figure 3.11-P2X4 functional mutant scan, with P2X4 monomer for context: (Left) a scan of functional 10 amino acid 
mutants for P2X4 showing the percentage inhibition when in the presence of 20µM 5-BDBD compared to only ATP. For all 
mutant receptors n=5 and for the wildtype receptor n=26. (Right) a figure showing the quaternary structure of a P2X4 
monomer with coloured sections corresponding to the colours of the mutants compiling the response reduction graph. 
Significant difference from the wildtype is denoted with an *. (Bottom) a figure highlighting only the 81-90 region of the 
P2X4 monomer. 
In figure 3.11 above you can see that for almost all mutants there was a consistent level of 
inhibition with the lowest other than 81-90 being at 70.5 ± 3.8% (331-338) and the highest 
recorded inhibition being 85.6 ± 5.3% (211-220). 20µM of 5-BDBD caused an average 
inhibition to the wildtype receptor of 72.1 ± 0.9% which sits well within this range. There 
was no significant difference between any of these mutants and the wildtype receptor.  
For the mutant 81-90 however there was an inhibitionof 29.4 ± 4.3%, showing that this 
mutant was much less sensitive to 5-BDBD than the others tested in this scan. The 81-90 
mutant was significantly different to the wild type receptor (p=4.8x10-4) and to all other 
functional mutants when performing a Kruskal-Wallis ANOVA. 
 
3.7 Point Mutation Within the 81-90 Chimera 
Once it had been established that the 81-90 chimera significantly reduced the inhibition of 
P2X4 by 5-BDBD, point mutations that could be made within this area were considered. 
Mutation of the 81st residue was chosen as this was the only residue within the stretch 
which was unique to hP2X4 within the 7 hP2X receptors. This mutation involved replacing a 
















Figure 3.12-A comparison WT to 81-point mutant response reduction: A comparison between the response reductions 
elicited by 5-BDBD at the wildtype receptor (WT) and the 81-point mutant receptor. There are error bars present and an * 
to signify a statistically significant difference between the two data sets (p=0.009) (n=5). 
When directly comparing the 81-point mutant receptor to the wildtype an ATP 
concentration of 30µM was used along with 20µM of 5-BDBD. The inhibition at the WT 
receptor was 79.2 ± 3.5% which was similar to that found in the receptor scan in section 3.6 
(72.1 ± 0.9%) with the higher variability due to the lower number of repeats in this 
experiment. For the 81 mutant the average inhibition was 42.7 ± 4.2%. When performing a 
Kruskal-Wallis ANOVA the data sets were significantly different (p=0.009) showing that 
mutation of the 81st residue significantly reduces the inhibitory capability of 5-BDBD. 
 
3.8 ATP Concentration Response Curves for the Mutants of Interest 
An ATP concentration response was conducted for both of the mutant receptors of interest 




Figure 3.13-ATP concentration response curves for the mutant receptors of interest: Two ATP concentration response 
curve for the 81-90 chimeric receptor (left) and the 81-point mutant receptor (right). They are both fit with the Hill1 
equation in order to aid in the derivation of an EC50. All points are presented with standard error from the five repeats at 
each concentration for both receptors (n=5). 
 
For both mutant receptors the maximal response was achieved at 30µM and there was a 
desensitisation at 100µM which was the same as what was seen from the wildtype receptor 
in figure 3.. The EC50 for the 81-90 chimera was found to be 862.8 ± 318.6nM and for the 
81-point mutant it was 573.3 ± 115.3nM. When compared to the EC50 value derived from 
the wildtype receptor (379.8 ± 99.0nM) using a post-hoc Kruskal-Wallis ANOVA, there was 
no significant difference between any of the three receptors. 
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Chapter 4: Discussion  
4.1 Transfection Optimisation 
1321N1 cells were chosen for this project due to them not endogenously expressing any 
purinergic receptors (Abbracchio et al, 2016), which would mean that there should be no 
response to ATP from blank (non-transfected) cells. This would allow for easier analysis of 
data as the only response given after the addition of ATP should be from hP2X4 in both the 
stably and transiently transfected cells. This differs from other commonly used cell lines 
such as HEK293 and HeLa cell lines. HEK cells for instance, endogenously express P2Y 
receptors which are stimulated by ATP (Schachter et al, 1997; Fischer et al, 2005; Romanov 
et al, 2007). This means that when looking for P2X4 response in stably transfected HEK cells, 
the response of blank HEK cells must be subtracted which can lead to variable results and 
often at high antagonist concentrations give negative results depending on the size of the 
blank response. In HEK cells expressing P2X4 the majority of the response can often be 
made up of P2Y receptor activity, providing only a small margin for error when looking at 
P2X4 activity. In this study the blanks were subtracted from the data gathered, but this was 
only as a precautionary measure in order to remove the background noise which occurs 
throughout the assays. Using 1321N1 cells was therefore beneficial as it gave a move clear 
picture of the effect of 5-BDBD solely on the hP2X4 receptor. 
The issue that was found with 1321N1 cells however was that there was little literature 
denoting the best conditions for transfection of these cells than the lines previously 
mentioned. Several studies had used 1321N1 cells transfected with GPCR’s, however the 
methods of transfection were often inconsistent or stably transfected cells were used, with 
this study adopting a transient transfection method (Charlton et al, 1996; Seye et al, 2004; 
Pugliese et al, 2009). When beginning to plan the optimisation of this protocol there was 
one paper which was very useful as it tested the effectiveness of several different 
techniques and some of the more common transfection reagents which were readily 
available within the lab (Marucci et al, 2011). In this review the group rated the transfection 
method based on two distinct categories, cell viability and transfection efficiency. Overall, it 
was found that microporation was the best technique to use for transfection of 1321N1 cells 
due to it having a ten-fold higher transfection efficiency than any of the other methods 
whilst having a 75% cell viability (3rd of the 5 methods tested). Microporation having a high 
rate of transfection efficiency but leading to a slightly lower than optimal cell viability, which 
is corroborated by several other studies (Lim et al, 2010; Halim et al, 2014), would naturally 
be seen as the primary method of 1321N1 cell transfection. However, the equipment to 
perform transfections via this method was not available within the lab. 
When looking at the reagent-based transfections described in this transfection optimisation 
paper (Marucci et al, 2011), FuGene stands out from the others which were also generic 
transfection reagents, readily available within the lab. FuGene gave the lowest cell viability 
but the third highest transfection efficiency and when looking at the data collected in 
section 3.1 this low cell viability may be a reason for the low responses achieved when using 
this reagent. FuGene in fact gave the lowest responses of the four reagents tested with a 
maximal F ratio of 0.165, showing that it may be an ineffective reagent for 1321N1 cells 
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despite being very good at transfecting other cell lines such as HeLa and HepG2 (Yamano et 
al, 2010). The next reagent tested was Polyfect, there was no documented attempt to 
transfect 1321N1 cells using Polyfect but again it was a readily available reagent which was 
adept at the transfection of other cell lines (Breunig et al, 2007). Polyfect didn’t produce any 
conditions which were significantly different from the blank response with a maximal F ratio 
of 0.21 achieved, meaning that it was not in contention to be used as the reagent in this 
study. 
Thirdly, X-treme Gene is a transfection reagent which has similar properties to another 
reagent in the paper called Arrest-in (Marucci et al, 2011). Arrest-in was found to have the 
second highest transfection efficiency and the second highest cell viability, suggesting that 
X-treme Gene could be one of the front runners. When testing X-treme gene at a range of 
conditions (similar to the other reagents) it was found that 3 of the 6 conditions gave a 
response significantly higher than the background with the most efficacious condition being 
at 0.3µl of reagent and 150ng per well of DNA which gave an F ratio response of 0.24. The 
Final reagent tested was Lipofectamine. In the aforementioned study Lipofectamine came 
fourth of five for both cell viability and transfection efficiency. However, Lipofectamine is a 
common reagent which is often used for RNA transfections and has the benefit of working 
via lipofection which allows for effective transfection in many cell lines, especially through 
cell culture methods (Carter et al, 2015). When testing Lipofectamine 4 of the 6 conditions 
tested gave a significantly higher F ratio than the blank with the highest being at 0.355 
(300ng of DNA and 0.5 µl of Lipofectamine per well). This condition gave the best response 
found across any of the reagents and is the condition set which would be used for the 
remaining transfections in this project. The reason for Lipofectamine being the most 
effective transfection reagent in this study may be that it is the only Liposomal reagent of 
the four tested which may be the preferred method of 1321N1 cell transfection because of 
the flexibility of lipofection, due to the aversion of this cell line to transfection. This higher 
range of transfection targets comes from the ability of the liposome containing the DNA to 
merge with the lipids on the cell surface allowing the contents of the liposome to empty 
into the cytoplasm of the cell (Balazs et al, 2011). Another possible reason for Lipofectamine 
being the most effective transfection reagent could be due to the low toxicity of lipofection 
compared to other methods. Although the 1321N1 cell transfection study (Marucci et al, 
2011) ranked Lipofectamine as 4th for cell viability, other studies have shown that 
Lipofection causes low toxicity to the cells which could explain the higher responses found 









4.2 hP2X4 and hP2X2 EC50 and IC50 Value Derivation 
When looking at the ATP concentration response data generated in this study, an EC50 of 
479nM was derived for P2X4 which was significantly different from the P2X2 value of 1µM. 
This EC50 for P2X2 is similar to that found in several studies (North et al, 2009; Li et al, 2013; 
Ding et al, 1999). The significant difference between the two receptors suggests that there is 
a difference in the potency of ATP for the two. P2X2 being further to the right on an ATP 
concentration response would suggest that ATP is a less potent agonist for hP2X2 than it is 
for hP2X4. The other key difference that can be seen between the two receptors is that 
there is a desensitisation of the channel for P2X4 at 100µM and 300µM which does not 
occur for P2X2. This desensitisation is common for hP2X4 (Sim et al, 2007) and can be due to 
receptor internalisation at the cell surface or over-competition at the ligand binding site. 
The lack of desensitisation for P2X2 could be due to this receptor having a much slower rate 
of desensitisation which may not be seen within the 250 seconds of each assay (Volonte et 
al, 2009). An approximate EC50 ATP concentration (500nM for P2X4 and 1µM for P2X2) was 
used in the derivation of an IC50 value for each of the receptors moving forward.  
An IC50 of 873.9nM for 5-BDBD was derived from P2X4 with the maximal inhibition of 
response being 95% of the control. This IC50 was slightly higher than the 500nM found in 
2005 (Fischer et al, 2005) and slightly lower than the 1.2 µM found by Balasz’s group (Balasz 
et al, 2013) although this was conducted using patch clamp electrophysiology rather than a 
Flexstation III which can lead to higher IC50 and EC50 values. The derivation of an IC50 value 
allows for the comparison of the potency for different inhibitors of the same receptor. At 
P2X4 for example we can compare the potency of 5-BDBD to other selective P2X4 
antagonists such as BX430 and PSB12054. For BX430 an IC50 value of 540nM was found 
when using patch clamp analysis (Ase et al, 2015) and 1.6µM when performing a Ca2+ assay 
with a Flesxstation III (Layhadi et al, 2018). PSB-12054 on the other hand using patch clamp 
an IC50 of 190nM was derived (Ase et al, 2015) and using a Ca2+ influx assay it was found to 
be 189nM (Hernandez-Olmos, 2012). These three selective antagonists can therefore be 
compared for potency using the calcium-based assays for reference due to the nature of this 
study. 5-BDBD based on the evidence is a more potent inhibitor than BX430 and less potent 
that PSB-12054 giving a ranking of PSB-12054>5-BDBD>BX430. 
An IC50 value could not be derived for P2X2 due to not being able to fit a Hill1 equation to 
the data. This occurred due to the lack of inhibition seen for the concentrations tested. 
There was no concentration -dependent inhibition of the receptor seen, with there was no 
significant difference between any of the concentrations in this range. The 5-BDBD 
concentrations 10nM to 10µM all had responses of between 85% and 102% of the control 
response, indicating that 5-BDBD has little or no effect on P2X2 Ca2+ response within this 
range. Moving forward the 5-BDBD concentration used for screening mutants was agreed to 
be 20µM as this caused an 85% reduction in P2X4 response without significantly reducing 
P2X2 response (14% reduction).  
The range of concentrations used for IC50 value derivation (300pM to 50µM) was larger 
than for EC50 (10nM to 300µM). For IC50 curves two different concentration ranges were 
used, 300pM to 50µM for P2X4 and 10nM to 30µM for P2X2. The reason for the P2X4 IC50 
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concentration range going to such a low point was due to issues found when trying to use 
10nM or 30nM as the lowest concentrations in preliminary tests. The issue with using these 
concentrations as the lowest in the study was that 5-BDBD has not titrated back to 100% of 
control response, meaning that 5-BDBD was still having a small inhibitory effect on the 
receptor at this concentration. This was not the case for P2X2 as at 10nM the Ca2+ response 
was already at 100% of control response so no smaller concentrations were required to be 
tested. It can be seen in figure 3.6 that at 30nM the normalised response is still below 100% 
of the control and that the data had not plateaued at this point meaning that it is difficult to 
fit a Hill1 equation to the curve, making the derivation of an IC50 value more difficult. For 
these reasons the range of 5-BDBD concentrations tested against hP2X4 was extended at 
the lower end to 300pM. 
The trace data in section 3.4 is a clear indication of the effect 5-BDBD has on a normal P2X4 
response. The Flexstation trace is key to all of the results collected in this study as the peak 
response from each trace, for each well tested is the primary data point which allowed for 
the comparison of different conditions in this study. In figure 3.8 it can be seen that 5-BDBD 
reduces the peak F ratio by 47.4% which is similar to the response reduction found when 
running under the same conditions in section 3.5 (52.0% response reduction). Figure 3.8 
also shows that the shape of the graph changes with there being less of a rapid increase to 
the peak F ratio after the addition of agonist (usually occurs within 10 seconds of addition). 
For the trace with 5-BDBD present the peak is reached after 110 seconds of the assay. This 
changes another metric which the inhibition of 5-BDBD could be measured by: area under 
the curve. In this study peak F ratio was used rather than area under the curve due to the 
ease of data analysis when conducting the receptor scan and the fact that the ‘peak’ 
response achieved is not dependent on both the rate of desensitisation and the maximal 
response achieved in the assay. This should mean that using the peak response metric 
rather than area under the curve should lead to a lower variability across the data set. 
However, if this project was to be repeated using both of these metrics throughout could be 
interesting to see how 5-BDBD effects the amplitude of response and the trace data. 
4.3 5-BDBD concentration Response 
In this study, the lower concentrations of 5-BDBD tested for (up until 10µM) showed no 
significance in either EC50 value or maxima reduction from the control. One influential 
study showing the action of 5-BDBD concluded that there was a rightward shift in the ATP 
concentration response curve, without the maximal response changing and therefore that 
5-BDBD is a competitive antagonist (Balasz et al 2013). This is due in some part to the small 
number of concentrations which were tested for in the study conducted by this group, who 
noted the difference between ATP (control), 2µM and 20µM. There only being two 
concentrations of 5-BDBD and the wide difference between these two may prevent the 
small changes in maxima and EC50 being picked up. In this project 3µM and 20µM are 
almost equivalent to the 2µM and 20µM used in the aforementioned study. In section 3.5 it 
can be seen that 20µM had a significantly higher EC50 than the control but 3µM did not. If 
only looking at this metric you can assume that the increase in EC50 and shift rightwards on 
the concentration response curve shows that 5-BDBD is competitive. However, at 20µM 
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there is also a significant reduction in the maxima from the control shown in figure 3.9 and 
table 2. In the study conducted by Balasz’s group there was ‘no change in the magnitude of 
maximal stimulation’. This difference found between the two studies may be due to the 
different methods used, with patch clamp being employed for Balasz’s study and this study 
using a Flexstation based protocol. Based on the different cations being tested for in these 
protocols (sodium for patch clamp and calcium for the Flexstation) and the contrast in data 
collection methods, this could explain the differences in the maximum response elicited 
after 5-BDBD addition.  
The data in table 2 shows that with increasing 5-BDBD concentration there are two clear 
trends. An increase in EC50 value and a decrease in normalised maximal response achieved. 
In terms of EC50, this trend becomes statistically significant for 10µM and above. For the 
maximal response, it is significant at 20µM and 30µM only. This could be a reason for the 
belief that 5-BDBD is non-competitive, as tests using lower concentrations with small 
incremental changes may see the change in EC50 value before the reduction in maxima. This 
can be seen with the differences between ATP, 1µM and 3µM in my study. The maximal 
response achieved at these concentrations were 100%, 104% and 99% respectively which 
when plotted on a concentration response curve will show almost no difference in the 
maximal response but the EC50 value changes from 0.38 µM (ATP) to 3.1 µM (1µM) and 3.7 
µM (3µM), which will be more easily visible due to the rightward shift of the curve.  
This may be the reason that testing the action of 5-BDBD at low concentrations can produce 
the thought that it acts competitively as there is a trend to the right between these two 
concentrations, but the max response remains very similar. This shift, without a reduction, 
was also documented by a previous member of my lab (Bin Ahmad, 2018) who found that 
addition of 1.9µM of 5-BDBD (the derived IC50) caused a rightward shift of the 
concentration response curve and gave a significantly higher EC50 value than ATP without 5-
BDBD, without affecting the maximal response. Based on this data it would be appropriate 
to conclude that 5-BDBD acts competitively. However, based on 20µM and 30µM 
significantly reducing the maxima, it would be more appropriate to say that it shows mixed 
modality in this study. The working explanation for this may be that the antagonist binds to 
an allosteric site which is close to the agonist binding site. This can affect agonist binding at 
low concentrations resulting in the mode of action looking competitive at low 
concentrations but eliciting a non-competitive effect at higher concentrations. A second 
theory for why this occurs could be due to there being two or more sites where 5-BDBD can 
bind to the receptor. The higher affinity site could be in or near the agonist binding site and 
a lower affinity site, at an allosteric location. From the data collected it can be taken that 5-
BDBD acts non-competitively at human P2X4. Thirdly, the explanation could be that 5-BDBD 
binding to an allosteric site on P2X4 could cause these effects in tandem as there are other 






4.4 Functional Mutant Receptor Scan 
When conducting a scan of the receptor to look for areas of interest, a similar method had 
previously been used in a similar study (Ase et al, 2019) where several residues were 
mutated using a PCR based mutagenesis method in order to find residues which were key to 
BX430 action at P2X4. How this experiment differed however is that instead of mutating 
single residues which had been found to be conserved between the different species which 
were sensitive to BX430, 10 amino acid stretches of the receptor’s extracellular domain 
were replaced with aligned sections from P2X2 which was shown to be significantly less 
sensitive to 5-BDBD than P2X4 for the concentrations tested. 
When conducting the scan in section3.6, 5 repeats without 5-BDBD and 5 with 5-BDBD were 
compared to see the inhibition caused by 20µM of the inhibitor. If there is a section of the 
receptor which may be important for 5-BDBD action, you would expect to see a significantly 
lower inhibition due to potentially important residues within that mutant being removed.  
In the scan of the receptor, it appeared that all bar one of the mutants were within a tight 
range between 70.5% and 85.6%, comparable to 5-BDBD inhibition of the wildtype receptor. 
This would suggest that the stretch of amino acids which had been replaced were not 
necessary for 5-BDBD action because if a residue which is essential to 5-BDBD action is 
removed you would expect to see a significant reduction in percentage inhibition. For one 
mutant however (81-90), there was a significant reduction in inhibition when challenged 
with 5-BDBD. Indicating that this region does contains one or several residues which may be 
important in eliciting the action of 5-BDBD at hP2X4.  
This region may be important as it is just upstream of two key residues, K70 and K72, which 
are involved in ATP binding as they control the coordination of oxygens on the phosphate 
groups (K70) and the coordination of γ-phosphate groups (K72). 81-90 is the closest 
functional mutant to the binding site on this side of the monomer as the 71-80 mutant was 
non-functional, possibly due to removal of these important residues. This would likely result 
in the 71-80 mutant not being able to coordinate the ATP molecules in the binding groove, 
resulting in no response to ATP (what was deemed as a non-functional).  K70 and K72 are 
found in the binding pocket between the left flipper and head domain, towards the head at 
the edge of this pocket. 5-BDBD interacting with the receptor within close proximity to the 
ligand binding site could explain the mixed modal effects that are seen in the 5-BDBD ATP 
concentration response section (3.5). If the molecule interacts with the receptor closely to 
the ligand binding site it could perturb the entry of ATP at lower concentrations as it may 
obscure part of the entrance, leading to the decrease in potency of ATP for the receptor 
seen. At higher concentrations of 5-BDBD this effect on potency could still be present in the 
form of reduced ATP entry but then be outweighed by the allosteric effect of the inhibitor. 
This allosteric effect causes the decrease in efficacy seen in section 3.5. The allosteric effect 
elicited by 5-BDBD is likely to be due to a change in the conformation of the channel or the 
receptor dynamics (Nusinov and Tsai, 2013). Traditionally it was thought that binding of an 
allosteric inhibitor leads to a conformational change of the protein (Tsai et al, 2009) but 
formal descriptions of allosteric now include changes in dynamics for the protein (Hilser 
et al, 2012). This means that the interaction of 5-BDBD with this allosteric site could cause a 
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change in shape of the ligand binding site, resulting in a reduction in efficacy or a change in 
channel dynamics such as perturbing the flexing of the lower body domain of P2X4, 
therefore impeding the activity of P2X4. 
 
4.5 Residues Phenylalanine 81 to Valine90 
When there had been statistical confirmation that the 81-90 chimera was an area of interest 
for this study, a more in-depth analysis of this region was undertaken including a direct 
sequence comparison between hP2X4 and the other human P2X receptors. 
Table 3-An alignment of the 7 P2X receptors in humans between residue 81 and 90: An aligned comparison between the 
7 P2X receptors in humans, with a particular focus on the residues from 81 to 90 in the primary sequence. The highlighted 
residues were possible mutation points.  
   
Using table 3 we were able to visualise the differences in residues between the P2X 
receptors in humans, these differences could be key to 5-BDBD inhibition due to it being 
selective for P2X4 over other receptors in the family (Jacobson and Muller, 2016). If the 
selectivity that 5-BDBD has for P2X4 is due to an interaction which occurs with the receptor 
at one or multiple residues within this area, it would stand to reason that the residue would 
be unique to P2X4 or at least possessed by few other P2X receptors. 
When comparing the Sequences three areas within this group stood out, two for being fairly 
unique and one for being different to P2X2 which was used in the study when making 
chimeras and point mutations. These key residues were highlighted in table 3 above as 
green (81st residue), yellow (83rd residue) and blue (the 87th and 88th residues). All other 
residues were conserved between P2X2 and P2X4 other than residue 82 where P2X2 has a 
Lysine instead of an arginine. This difference should does not stand out however as the 
amino acids are both positively charged and are of a similar size with arginine being the 
larger of the two. Arginine is also shared by 3 of the other P2X receptors rendering it 





Aligned P2X  
P2X 
Receptor 81 82 83 84 85 86 87 88 89 90 
P2X1 P Q V W D V A D Y V 
P2X2 H K V W D V E E Y V 
P2X3 N R V M D V S D Y V 
P2X4 F R I W D V A D Y V 
P2X5 Q R I W D V A D Y V 
P2X6 N R L W D V A D Y V 
P2X7 H S V F D T A D Y T 
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4.5.1 Residue Phenylalanine 81 
The 81st residue (a phenylalanine) was marked as of interest as it is shared by none of the 
other P2X receptors and this residue is one which is the most variable within the stretch 
with 5 different amino acids between the receptors (the most of any residue in this 
alignment) and being the only residue which doesn’t have a single amino acid shared by four 
or more of the P2X receptors (82nd and 83rd both having four which share arginine and 
valine respectively). When looking at differences between the chosen residues it is most 
important to understand the difference between the P2X4 and P2X2 amino acids as P2X2 
has been used in the mutant scan and will be used to make any point mutant. For the 81st 
residue in P2X4 there is a phenylalanine which is a non-polar amino acid with an aromatic r-
group. For P2X2 at this residue a histidine is present (also found for P2X7) which is positively 
charged and has an imidazole functional group. This difference in polarity between the two 
residues could account for the interaction of 5-BDBD selectively over P2X2. When looking at 
the amino acids which the other P2X receptors possess at this point; asparagine (P2X3 and 
P2X6) and glutamate (P2X5) are both polar uncharged amino acids. The only receptor which 









Figure 4.1-The chemical structures of 5-BDBD and Phenylalanine: The chemical structures of 5-BDBD (left) and 
Phenylalanine (right) showing their functional groups. There being two aromatic rings on 5-BDBD one on the middle left 
and one on the bottom right of the molecule, for Phenylalanine the ring can be seen on the left of the molecule (Sigma 
Aldrich, 2019; ChEBI, 2019).  
There are two clear distinctions between phenylalanine at P2X4 and the other amino acids 
present in the other 6 receptors. Firstly, is that all bar P2X1 has a polar residue, where P2X4 
has a non-polar residue. This would however rule out 5-BDBD being attracted to P2X4 due 
to its polarity as non-polar molecules will not attract each other based on their polarity. 
Secondly that phenylalanine is the only amino acid which has an aromatic r-group. When 
looking at the structure of 5-BDBD it has two aromatic groups one with a bromide attached 
and one attached to the main bulk of the molecule. With phenylalanine having an aromatic 
group it would stand to reason that one of the aromatic groups  from 5-BDBD and the 
aromatic group from phenylalanine at residue 81 in P2X4 could interact via a process called 
stacking. This interaction occurs due to the alignment of opposing electrostatic potentials 
between the electrons in the pi rings of the two aromatic groups (Wheeler et al, 2014). The 
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small positive charge from one ring attracts the small negative charge from the other, 
producing a non-covalent interaction between the two rings (Rahman et al, 2015). The fact 
that P2X4 is the only receptor in the family which has an amino acid with an aromatic group 
at this point would suggest that this is more likely to be the reason for 5-BDBD interacting at 
point 81 than the polarity of the amino acids at this point in the other receptors, especially 
bearing in mind that P2X1 also has a non-polar amino acid at this point. 
 
4.5.2 Residue Isoleucine 83 
The second residue of interest in this section is at position 83. For P2X4 at this point the 
amino acid is isoleucine which is only shared by one other receptor in the family P2X5. 
When looking at which amino acids are present for the receptors there is valine (P2X1, 2, 3 
and P2X7) and leucine (P2X6). When looking at the properties of these amino acids they are 
all non-polar and all have aliphatic r groups. This shows that the amino acids will only be 
marginally different chemically, resulting in there being little room for selectivity based on 
this residue alone. 
 
4.5.3 Residue Alanine 87 and Aspartic Acid 88 
For residue 87 and 88 there were many receptors in the family which shared the same 
amino acids at this point (alanine and aspartic acid respectively) with P2X1,P2X4,P2X5, P2X6 
and P2X7 all having A and D at residue 87 and 88. When comparing these residues to P2X2 
however there was a difference which was studied to see if this region could be important. 
At P2X2 residue 87 and 88 are both glutamic acids. For position 88 for both receptors the 
amino acids are polar with acidic r groups, with the only difference being the length of the r 
group chain. At position 87 on the other hand, an alanine which is non polar with an 
aliphatic r group is substituted for a polar and acidic glutamic acid. This would result in a 
more highly charged section of the receptor which may repel the 5-BDBD and stop it from 
binding to hP2X2. However, whilst this would account for the selectivity of 5-BDBD for 
hP2X4 over P2X2, it would not account for its selectivity over the other P2X receptors with 4 
sharing these two residues. 
When looking at this region of the receptor for humans, rats and mice it can be seen that 
from 81-90 is conserved between the species providing possible evidence for why 5-BDBD is 
able to antagonise rat and mouse P2X4 (Coddou et al, 2018: Yu et al, 2018: Ledderose et al, 
2018). Adding further weight to the conclusion that one of the residues within this region 
plays a role in 5-BDBD action. 
Overall based on the evidence presented it was clear that P2X4 selectivity for 5-BDBD comes 
from within the 81-90 region and that the most likely point of interaction for the inhibitor 
would be at residue 81. This is not only due to it being unique amongst the other receptors 
in the primary sequence, but also the presence of an aromatic group providing a method of 
interaction with 5-BDBD.  
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4.5.4 Residue 81 Percentage Inhibition Derivation 
Once residue 81 had been singled out the point mutant was produced and tested for the 
inhibition elicited by 20µM of 5-BDBD, in much the same way as for the scan of the receptor 
in section 3.6.  
The WT inhibition was 79.2 ± 3.5% which is higher than was found for the overall scan of the 
receptor, but this would be due to the number of repeats which were undertaken for the 
WT receptor in this section resulting in less standard error and a truer value for than in 
section 3.7. The inhibition found was however well within the normal range specified of 
70.45% to 85.59%.  For the point mutant the inhibition was 42.7 ± 4.2% which is significantly 
lower than at the wildtype (p=0.009) suggesting that this mutation significantly reduced the 
sensitivity of the receptor to 5-BDBD.  
When comparing the 81-point mutant to the 81-90 chimera which stood out from section 
3.6, the point mutant has a higher inhibition (13.3%) than the chimera suggesting that it 
conveys less sensitivity to 5-BDBD. However, when performing a Kruskal-Wallis ANOVA 
there was no significant difference between the two data sets (p=0.076). This difference in 
sensitivity for 5-BDBD may suggest that 5-BDBD interacts with more than one residue in this 
stretch of the receptor. This would however presumably lead to issues with selectivity for 
P2X4 over the other receptors unless the 81st residue was a higher affinity interaction site 
and a further residue or section within the 81-90 region accounts for a lower affinity 
interaction site. This would account for the reason that at high concentrations of 5-BDBD 
P2X1 and P2X3 are slightly inhibited in rats (Coddou et al, 2019). However, when looking at 
the possible areas of interest within the 81-90 region, neither residue 83 or 87 and 88 show 
a connection to P2X1 or P2X3 over the other receptors in the family. Leading to the possible 
conclusion that with a higher n number for both the chimera and point mutant, they 















Figure 4.2-The P2X4 ATP binding site relative to residue 81: (Left) A colour coordinated image of a P2X4 monomer with 
the transmembrane (green), body (red), dorsal fin (dark grey), head (turquoise) right flipper (light grey) and left flipper 
(blue) domains marked in their own colours to give context for the position of residue 81 in regard to the other features of 
the monomer. (Right) A diagram showing the points of interaction between an ATP molecule and the two subunits in a 
functional trimer of the receptor with A denoting the contribution from one monomer and B the contribution from 
another. Figure taken from a paper published by Chataigneau (2013). (Bottom) An image showing the position of the 81st 
residue on the P2X4 trimer in relation to the ATP binding site (key residues coloured red) and the binding site for BX-430 
found in the Ase paper (Ase et al, 2019) (key residues coloured in blue). 
 
Figure 4.2 shows the colour coordinated P2X4 monomer with the distinct domains 
highlighted in a different colour and with 81 denoting where the residue of interest is 
situated. On the right of this figure the interactions between the neighbouring monomers 
and ATP can be seen with the residues from subunit B coming from the tip of the dorsal fin, 
the left flipper domain and the lower body domain. This would mean that the ATP binding 
site is indeed just downstream of the residue of interest (81) which could suggest that the 
interaction of 5-BDBD with the receptor at residue 81 could perturb ATP entry into the 
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binding pocket at low concentrations as had been hypothesised. When looking at the 
bottom image of figure 4.2, the position of residue 81 is relatively close to the ATP binding 
site and very close to the binding site for BX-430 (another small molecule allosteric inhibitor 
of P2X4) which was identified in a 2019 paper (Ase et al, 2019). In the aforementioned 
paper, the group mutated single residues within a region of the ectodomain which was 
highly conserved among the receptor family. They found that when residue Ile315 (in 
zebrafish, Ile312 in humans) was mutated to a threonine residue, there was a large 
reduction in sensitivity of P2X4 for BX-430. In this paper they also found that sensitivity to 
BX-430 can be restored in rats and mice (which are insensitive to the inhibitor) via inserting 
isoleucine at this position. The suggested mechanism of action for BX-430 in this paper is 
through a structural locking of the ectodomain in this specific region caused by the binding 
of BX-430 at the site. Due to the exceedingly close proximity of residue 81 to this BX-430 this 
could be a possible mechanism of action for 5-BDBD also, causing a locking of the receptor 
in a closed state and therefore not allowing the entry of calcium ions into the cell. 
There are examples of allosteric inhibitors which can both reduce maximal response and 
reduce potency of an agonist without being close to the ligand binding site.  This is the case 
for papaverine which is a non-selective smooth muscle relaxant which is most often used as 
a drug to induce vasodilation (Sonnenfield et al, 1980; Tanyeli et al, 2019). When looking at 
a concentration response curve for this receptor antagonist there are similarities to what is 
seen for 5-BDBD with a reduction in the maximal response and a reduction in potency with 
higher concentrations (Ameer et al, 2010). As papaverine is a non-selective antagonist and 
elicits its effect through several receptors it is likely that the mixed modality of this 
inhibition is due to the activity of the antagonist rather than its positioning in regard to the 
ligand binding site.  
4.5.5 Mutant Receptor ATP Concentration Response Curves 
In figure 3.14 the two receptors of interest were challenged with the same range of ATP 
concentrations as the wildtype receptor for the derivation of its EC50. This was done in 
order to derive an EC50 for the two mutant receptors and see if there was any significant 
difference in potency of ATP for the mutant receptors over the wildtype. Any changes in ATP 
potency for these receptors could be a cause for the lower response reductions seen when 
testing these receptors with 5-BDBD. 
When comparing the average EC50 values for the receptors a p value of 1 was found when 
comparing the 81-point mutant to both the wildtype receptor and the 81-90 chimera. When 
comparing the 81-90 receptor to the wildtype p=0.45. As the level for significance is p<0.05 
it can be seen that the differences between the receptors in terms of ATP potency are not 
close to the level of significance. This allows me to be sure that the effect seen with both of 
these mutant receptors (the lower response reduction) was due to one of the residues 
which were changed eliciting the effects of 5-BDBD on P2X4 rather than the substitution 






Based on the results found in this project, several conclusions can be made regarding the 
antagonism of hP2X4R by 5-BDBD. Firstly, I would conclude that, in contrast to the consensus 
view in the published literature, 5-BDBD is a non-competitive antagonist due to the results 
obtained in section 3.5 which show that unlike a competitive antagonist, 5-BDBD causes a 
reduction in efficacy and a decrease in potency of ATP for the receptor. This effect would be 
atypical for a purely competitive antagonist and so led to the pursuit of an allosteric binding 
site for 5-BDBD. The second conclusion to take is that 5-BDBD interacts with residue 81 in 
the primary sequence which is situated on the lower body domain of the P2X4 monomer, 
just upstream from the ligand binding site. This residue is unique to P2X4 within the 
receptor family and is likely to confer the selectivity of 5-BDBD for P2X4 over the other 6 
receptors. This selectivity is likely to come due to the aromatic groups of 5-BDBD and the 
phenylalanine residue at position 81 ‘stacking’ which allows 5-BDBD to uniquely interact 
with this receptor. The final conclusion to take is that residue 81 is important for facilitating 
the inhibitory effects of 5-BDBD on hP2X4 receptors as replacement of this residue with a 
histidine (present at residue 81 in P2X2) leads to a significant reduction in sensitivity to 5-
BDBD. This would suggest that residue 81 can confer sensitivity of the receptor to 5-BDBD. 
With this increased understanding of one of the few selective antagonists for P2X4, the 
hope is that antagonism of this receptor can be better understood and the movement 
towards a therapy for the pathophysiological processes which it underpins can be increased 
as more information about this receptor is elucidated. Further studies using this antagonist 
could aim to find any other potential allosteric site within the non-functional mutant regions 
of the receptor. Future studies may also endeavour to find the mechanistic properties of 5-
BDBD which could aid in the production of further small molecule antagonists for P2X4. 
Furthermore, computer modelling of 5-BDBD binding to hP2X4 could allow for a certainty 
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